Hartwig Huland

Q: What Schools Are Affiliated With Hartwig Huland

Hartwig Huland is affiliated with the following schools: University of Michigan, Free University of Berlin, University of Hamburg, University of Ferrara, Université Laval

Hartwig Huland's AcademicInfluence.com Rankings

Hartwig Huland

Biology

#7507

World Rank

#10442

Historical Rank

Computational Biology

#142

World Rank

#142

Historical Rank

Molecular Biology

#871

World Rank

#894

Historical Rank

biology Degrees

Download Badge

Biology

Hartwig Huland's Degrees

PhD Molecular Biology University of California, San Francisco
Bachelors Biochemistry Stanford University

Why Is Hartwig Huland Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Hartwig Huland's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. (2008) (447)
Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. (2016) (404)
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. (2003) (393)
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. (2003) (364)
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. (2013) (308)
Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. (2008) (279)
Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. (1991) (239)
High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. (2006) (227)
High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer (2011) (223)
Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. (2016) (218)
Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients (2004) (216)
Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. (2006) (207)
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. (2002) (205)
Urodynamic evaluation of changes in urinary control after radical retropubic prostatectomy. (1997) (203)
CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. (2013) (203)
Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. (2012) (202)
Clinical significance of p53 alterations in surgically treated prostate cancers (2008) (196)
Defining a standard set of patient-centered outcomes for men with localized prostate cancer. (2014) (195)
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. (2009) (182)
Open retropubic nerve-sparing radical prostatectomy. (2006) (181)
Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. (2005) (179)
Full functional-length urethral sphincter preservation during radical prostatectomy. (2011) (179)
Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. (2006) (176)
Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. (2003) (175)
Depression, anxiety, post-traumatic stress disorder and health-related quality of life and its association with social support in ambulatory prostate cancer patients. (2010) (175)
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. (2005) (162)
A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. (2001) (161)
Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer (2007) (158)
Systematic sextant biopsies in 651 patients referred for prostate evaluation. (1994) (154)
Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. (2011) (153)
Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. (2008) (152)
Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. (2018) (149)
Nerve distribution along the prostatic capsule. (2007) (142)
Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder (2006) (140)
A side by side comparison of cytology and biomarkers for bladder cancer detection. (2004) (140)
Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer (2008) (138)
Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. (2008) (136)
Patient-reported sexual function after nerve-sparing radical retropubic prostatectomy. (2002) (135)
Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. (2009) (135)
Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer (2010) (134)
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. (2013) (133)
Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer (2009) (131)
Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis (2009) (131)
Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. (2007) (128)
Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. (2005) (127)
Current technique of open intrafascial nerve-sparing retropubic prostatectomy. (2009) (127)
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers (2013) (125)
Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation (2006) (124)
Anatomic radical retropubic prostatectomy—long-term recurrence-free survival rates for localized prostate cancer (2006) (123)
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. (2009) (123)
A critical appraisal of logistic regression‐based nomograms, artificial neural networks, classification and regression‐tree models, look‐up tables and risk‐group stratification models for prostate cancer (2007) (122)
Pathological results and rates of treatment failure in high‐risk prostate cancer patients after radical prostatectomy (2011) (121)
Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). (2015) (118)
Prediction of postoperative sexual function after nerve sparing radical retropubic prostatectomy. (2006) (117)
Radical prostatectomy improves progression‐free and cancer‐specific survival in men with lymph node positive prostate cancer in the prostate‐specific antigen era: a confirmatory study (2011) (116)
Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failure. (2005) (111)
Circulating tumour‐associated plasma DNA represents an independent and informative predictor of prostate cancer (2006) (110)
Development and external validation of an extended 10-core biopsy nomogram. (2007) (110)
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. (2006) (110)
Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade (2011) (109)
A nomogram predicting long‐term biochemical recurrence after radical prostatectomy (2008) (108)
Detection of circulating tumour cells in peripheral blood of patients with advanced non‐metastatic bladder cancer (2011) (107)
Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. (2008) (107)
High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. (2013) (107)
Tumor cell deoxyribonucleic acid content and prognosis in human renal cell carcinoma. (1984) (106)
Expression and prognostic relevance of annexin A3 in prostate cancer. (2008) (106)
Local Therapy Improves Survival in Metastatic Prostate Cancer. (2017) (106)
Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. (1984) (105)
CXCR3 and CCR5 Positive T-Cell Recruitment in Acute Human Renal Allograft Rejection (2004) (105)
Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical Prostatectomy. (2016) (104)
Early Prostate-Specific Antigen Relapse after Radical Retropubic Prostatectomy:Prediction on the Basis of Preoperative andPostoperative Tumor Characteristics (1999) (103)
Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer (2014) (102)
Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer (2004) (101)
Currently used criteria for active surveillance in men with low‐risk prostate cancer (2008) (99)
Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Angiogenesis and Invasion of Human Urinary Bladder Cancer (2004) (98)
Stage‐dependent increase of orosomucoid and zinc‐alpha2‐glycoprotein in urinary bladder cancer (2005) (98)
Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. (2002) (97)
Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men (2008) (96)
Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. (2007) (95)
Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. (2004) (94)
Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies. (1996) (93)
Prostate cancer nomograms: an update. (2006) (91)
Prostate volume and adverse prostate cancer features: fact not artifact. (2007) (90)
Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. (2000) (89)
Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. (2003) (89)
Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. (2007) (89)
Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. (1989) (88)
Stage Migration in Clinically Localized Prostate Cancer (2000) (88)
Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage. (2010) (88)
Development and external validation of an extended repeat biopsy nomogram. (2007) (88)
A feasible and time-efficient adaptation of NeuroSAFE for da Vinci robot-assisted radical prostatectomy. (2014) (87)
Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ‐confined from locally‐advanced prostate cancer in total PSA‐levels below 10 ng/ml (2001) (87)
[Monoclonal antibodies in diagnosis and therapy]. (1989) (83)
Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. (1990) (82)
A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. (2002) (82)
Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. (2004) (81)
Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. (2002) (81)
Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. (1998) (80)
Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. (2007) (79)
Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of β(1,6)-Branched Oligosaccharides as a Marker of Tumor Progression (2012) (77)
Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. (2010) (77)
Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. (2018) (77)
CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer (2006) (76)
Human prostate cancer regulates generation and maturation of monocyte‐derived dendritic cells (2001) (75)
Long‐term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate‐specific antigen era (2009) (75)
Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. (2007) (74)
Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study. (2017) (73)
Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment? (2015) (73)
Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer (2012) (72)
Immunohistochemical detection of p53 protein in human prostatic cancer. (1994) (71)
Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients. (1983) (71)
Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. (2003) (71)
Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy. (2006) (70)
Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer (2003) (69)
Monoclonal antibody 486 P 3/12: a valuable bladder carcinoma marker for immunocytology. (1987) (69)
Basic principles of anatomy for optimal surgical treatment of prostate cancer (2007) (68)
Rectourinary fistula repair using the Latzko technique. (1999) (67)
Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. (2019) (67)
Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients (2008) (66)
Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis? (2005) (66)
The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free‐to‐total prostate‐specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? (2010) (65)
Detection of tumor‐specific DNA in blood and bone marrow plasma from patients with prostate cancer (2007) (65)
A comparative study of robot‐assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures (2019) (61)
Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. (1992) (61)
TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. (2014) (60)
The effect of age on functional outcomes after radical prostatectomy. (2015) (60)
Thromboembolic Complication Rate after Radical Retropubic Prostatectomy (1998) (60)
Validation of a biopsy‐based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma (2002) (60)
MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large‐scale tissue microarrays (2013) (59)
Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. (2002) (59)
Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality (2019) (58)
Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. (1999) (57)
Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. (2007) (56)
Correlation of symptoms and results of direct bacterial localization in patients with urinary tract infections. (1984) (56)
Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer (2017) (56)
Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. (1997) (56)
Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. (2018) (55)
Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. (2017) (54)
Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer. (2002) (54)
Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum (2006) (54)
Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population. (1985) (53)
Digital rectal examination, imaging, and systematic-sextant biopsy in identifying operable lymph node-negative prostatic carcinoma. (1992) (53)
Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. (1999) (53)
Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. (2006) (53)
The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer (2003) (53)
Management of erectile dysfunction after radical prostatectomy in 2007 (2007) (53)
Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells (2005) (52)
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. (2003) (51)
Transition zone cancers undermine the predictive accuracy of Partin table stage predictions. (2005) (51)
High mitochondria content is associated with prostate cancer disease progression (2013) (51)
External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. (2015) (50)
Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men (2007) (50)
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy (2007) (49)
Photodynamic diagnosis using 5-aminolevulinic acid for the detection of positive surgical margins during radical prostatectomy in patients with carcinoma of the prostate: a multicentre, prospective, phase 2 trial of a diagnostic procedure. (2009) (49)
Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. (1999) (49)
Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy? (2003) (48)
Incidence of positive surgical margins after biopsy-selected nerve-sparing radical prostatectomy. (1998) (48)
Overview of interleukin-2 inhalation therapy. (2000) (47)
Marked gene transcript level alterations occur early during radical prostatectomy. (2008) (47)
Prostate cancers in the transition zone: Part 2; clinical aspects (2004) (47)
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. (2015) (47)
Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. (2004) (47)
Systematic biopsies and digital rectal examination to identify the nerve-sparing side for radical prostatectomy without risk of positive margin in patients with clinical stage T2, N0 prostatic carcinoma. (1994) (47)
The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. (2006) (47)
Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. (2017) (47)
Molecular Heterogeneity of Free PSA in Sera of Patients with Benign and Malignant Prostate Tumors (1999) (47)
External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. (2019) (46)
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy. (2015) (46)
βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. (2014) (46)
[F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study. (2010) (45)
Postoperative complications of contemporary open and robot‐assisted laparoscopic radical prostatectomy using standardised reporting systems (2018) (45)
Role of nomograms for prostate cancer in 2007 (2007) (45)
Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis. (2005) (44)
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. (2003) (44)
Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. (2005) (44)
The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. (2011) (44)
Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. (2003) (44)
Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. (2003) (44)
Urological findings in patients with neurosurgically treated tethered spinal cord. (1993) (43)
Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria (2016) (43)
Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. (2007) (43)
Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy (2017) (43)
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. (2009) (43)
Biochemical recurrence following radical prostatectomy: A comparison between prostate cancers located in different anatomical zones (2003) (43)
Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. (2015) (42)
Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis. (2004) (42)
Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests. (2002) (42)
The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. (2000) (41)
Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer (2008) (41)
Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer (2017) (41)
Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer (2015) (41)
Association of free‐prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue (2005) (40)
Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. (2011) (40)
Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer (2015) (40)
Magnetic Resonance Imaging of Prostate Cancer: Diffusion-Weighted Imaging in Comparison With Sextant Biopsy (2011) (40)
Monoclonal antibodies for characterization of the heterogeneity of normal and malignant transitional cells. (1987) (40)
Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. (2002) (39)
Population‐Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment (2017) (39)
A new test to predict reversibility of hydronephrotic atrophy after stable partial unilateral ureteral obstruction. (1988) (39)
Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience. (1997) (37)
Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center. (2017) (37)
Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion (2018) (37)
Detection rate of histologically insignificant prostate cancer with systematic sextant biopsies and fine needle aspiration cytology. (2000) (37)
Effect of body mass index on histopathologic parameters: results of large European contemporary consecutive open radical prostatectomy series. (2009) (37)
Percent free prostate‐specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower (2008) (37)
Modified surgical technique to correct congenital and acquired penile curvature. (1991) (37)
High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. (2017) (36)
Functional and oncological outcomes of patients aged <50 years treated with radical prostatectomy for localised prostate cancer in a European population (2014) (36)
Deletion of 8p is an independent prognostic parameter in prostate cancer (2016) (36)
Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence? (2003) (35)
A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomy. (2014) (35)
CURRENTLY USED CRITERIA FOR ACTIVE SURVEILLANCE IN MEN WITH LOW RISK PROSTATE CANCER. AN ANALYSIS OF PATHOLOGICAL FEATURES (2008) (35)
Pyelonephritic scarring in 213 patients with upper and lower urinary tract infections: long-term followup. (1984) (35)
Relevance of p53 Gene Alterations for Tumor Recurrence in Patients with Superficial Transitional Cell Carcinoma of the Bladder (2001) (35)
MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. (2014) (34)
Differences in biopsy features between prostate cancers located in the transition and peripheral zone (2003) (34)
Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline (2017) (34)
Urinary concentration and tissue messenger RNA expression of monocyte chemoattractant protein-1 as an indicator of the degree of hydronephrotic atrophy in partial ureteral obstruction. (2002) (33)
Human Prostate Cancer Blocks the Generation of Dendritic Cells from CD34+ Hematopoietic Progenitors (2001) (33)
Survival benefit of local versus no local treatment for metastatic prostate cancer—Impact of baseline PSA and metastatic substages (2018) (33)
Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical Prostatectomy. (2017) (33)
Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ‐confined prostate cancer (2019) (33)
Chronic pyelonephritis as a cause of end stage renal disease. (1982) (33)
The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG‐negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression (2014) (33)
Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. (2009) (33)
Cohort profile: the TrueNTH Global Registry - an international registry to monitor and improve localised prostate cancer health outcomes (2017) (32)
Is year of radical prostatectomy a predictor of outcome in prostate cancer? (2004) (32)
Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer (2001) (32)
Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. (1997) (32)
The feasibility of prostate cancer detection by triple spectroscopy. (2009) (32)
Quantitative biopsy pathology for the prediction of pathologically organ‐confined prostate carcinoma (2003) (31)
Early complication of anatomical radical retropubic prostatectomy: lessons from a single-center experience. (1997) (31)
Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG‐fusion positive and PTEN deleted prostate cancers (2016) (31)
Prognostic significance of a positive surgical margin in pathologically organ‐confined prostate cancer (2010) (31)
An easy and safe approach to separating Denonvilliers' fascia from rectum during radical retropubic prostatectomy. (1999) (31)
Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a German Tertiary-care Center. (2019) (30)
Radical Prostatectomy: Options and Issues (2000) (30)
Frequent p16/MTS1 Inactivation in Early Stages of Urothelial Carcinoma of the Bladder Is Not Associated with Tumor Recurrence (2001) (30)
Partin Tables cannot accurately predict the pathological stage at radical prostatectomy. (2009) (30)
Tumor Characteristics and Oncologic Outcome after Radical Prostatectomy in Men 75 Years Old or Older. (2016) (30)
Molecular cancer phenotype in normal prostate tissue. (2009) (29)
Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. (2008) (29)
HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. (2015) (29)
A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer (2008) (29)
Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients (2016) (28)
Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients (2011) (28)
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. (2005) (28)
Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death (2021) (28)
[Carcinoma in situ of the testis: clinical significance, diagnosis and therapy]. (1989) (28)
Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. (1991) (27)
Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging. (2003) (27)
The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer. (1998) (27)
Hydronephrotic atrophy after stable mild or severe partial ureteral obstruction: natural history and recovery after relief of obstruction. (1990) (27)
High-Grade Prostatic Intraepithelial Neoplasia in Cystoprostatectomy Specimens (2001) (27)
Endo-urological cold-knife incision for ureteral stenosis after renal transplantation. (1994) (27)
THE ETIOLOGY OF BLADDER CANCER‐ARE THERE ANY NEW CLUES OR PREDICTORS OF BEHAVIOR? (1995) (26)
[Perioperative and postoperative complications of pelvic lymphadenectomy and radical prostatectomy in 320 consecutive patients]. (1995) (26)
Importance of baseline potency rate assessment of men diagnosed with clinically localized prostate cancer prior to radical prostatectomy. (2009) (26)
Sensitivity of urinary quantitative immunocytology with monoclonal antibody 486 P3/12 in 241 unselected patients with bladder carcinoma. (1991) (26)
Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients (2006) (26)
The novel nomogram of Gleason sum upgrade: Possible application for the eligible criteria of low dose rate brachytherapy (2010) (26)
Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomy. (2007) (26)
The correction of penile curvature with the Essed–Schröder technique: a long‐term follow‐up assessing functional aspects and quality of life (2000) (26)
Noninvasive ultrasound in detecting and staging bladder carcinoma (1985) (25)
Improving outcome of surgical procedures is not possible without adequate quality measurement. (2014) (25)
Open and robot‐assisted radical retropubic prostatectomy in men receiving ongoing low‐dose aspirin medication: revisiting an old paradigm? (2014) (25)
Urethral closure pressure changes with age in men. (1996) (25)
Association between Lymph Node Counts and Oncological Outcomes in Lymph Node Positive Prostate Cancer. (2017) (25)
Ten-year experience of robot-assisted radical prostatectomy: the road from cherry-picking to standard procedure. (2017) (25)
Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? (2002) (25)
Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy (2003) (25)
Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2–10 ng/ml in 4,480 men (2007) (25)
Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer (2016) (24)
Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer (2019) (24)
Significance of high-grade prostatic intraepithelial neoplasia in needle biopsy specimens. (2001) (24)
The Impact of Anxiety and Depression on Surgical and Functional Outcomes in Patients Who Underwent Radical Prostatectomy. (2020) (24)
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. (2007) (24)
Deletion of 18q is a strong and independent prognostic feature in prostate cancer (2016) (24)
A test for the identification of relevant sympathetic nerve fibers during nerve sparing retroperitoneal lymphadenectomy. (1992) (24)
Unilateral prostate cancer cannot be accurately predicted in low-risk patients. (2010) (23)
Surgical management of prostate cancer: advances based on a rational approach to the data. (2005) (23)
Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer (2018) (23)
Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy. (2007) (23)
Tumor volume in insignificant prostate cancer: Increasing threshold gains increasing risk (2015) (23)
Inhibition of dendritic cell generation and function by serum from prostate cancer patients: correlation with serum-free PSA. (2007) (23)
Improvement of ureteroileal anastomosis in continent urinary diversion with modified Le Duc procedure. (1998) (23)
Transplantation of human renal cell carcinoma into NMRI nu/nu mice. II. Evaluation of response to vinblastine sulfate monotherapy. (1984) (22)
The presence of prostate cancer on saturation biopsy can be accurately predicted (2010) (22)
Advanced Prostate Cancer Is Associated with a Decrease in Serum Luteinizing Hormone (2000) (22)
A comprehensive analysis of transcript signatures of the phosphatidylinositol‐3 kinase/protein kinase B signal‐transduction pathway in prostate cancer (2008) (22)
Endoscopic bladder neck suspension (Stamey-Pereyra) in female urinary stress incontinence. Long-term follow-up of 66 patients. (1984) (22)
Is intraoperative electrostimulation of erectile nerves possible? (1999) (22)
Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer (2017) (22)
Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxis. (1990) (22)
Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy? (1997) (21)
Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). (1999) (21)
Vesicoureteral reflux in end stage renal disease. (1979) (21)
Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. (2013) (21)
Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. (2018) (21)
North American Population‐Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer (2017) (20)
Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial. (2019) (20)
Refluxing chimney versus nonrefluxing LeDuc ureteroileal anastomosis for orthotopic ileal neobladder: a comparative analysis for patients with bladder cancer. (2006) (20)
Major postoperative complications secondary to use of the Bookwalter self-retaining retractor. (2002) (20)
Health‐insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer (2007) (20)
Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer. (2000) (20)
Influence of low-molecular-weight heparin dosage on red blood cell transfusion, lymphocele rate and drainage duration after open radical prostatectomy. (2012) (20)
Cyclooxygenase‐2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma but does not predict recurrence (2003) (19)
Microsatellite alterations at chromosomes 9p, 13q, and 17p in nonmuscle-invasive transitional cell carcinomas of the urinary bladder. (1998) (19)
Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. (2019) (19)
Influence of cause on choice of therapy in 174 patients with erectile dysfunction. (1992) (19)
Autologous blood transfusion in radical prostatectomy: results in 263 patients. (1995) (19)
The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer (2016) (19)
Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. (2009) (19)
Deep Learning for Natural Language Processing in Urology: State-of-the-Art Automated Extraction of Detailed Pathologic Prostate Cancer Data From Narratively Written Electronic Health Records. (2018) (19)
Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer. (2000) (19)
Long-term results of the Stamey bladder neck suspension procedure: a patient questionnaire based outcome analysis. (1997) (19)
The value of histologic grading and staging, random biopsies, tumor and bladder mucosa blood group antigens, in predicting progression of superficial bladder cancer. (1984) (19)
Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy (2006) (19)
Pathophysiology of hydronephrotic atrophy: the cause and role of active preglomerular vasoconstriction. (1983) (19)
Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins (2017) (19)
Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy (2017) (19)
Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients (2018) (19)
Loss of Somatostatin Receptor Subtype 2 in Prostate Cancer Is Linked to an Aggressive Cancer Phenotype, High Tumor Cell Proliferation and Predicts Early Metastatic and Biochemical Relapse (2014) (18)
Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. (2016) (18)
Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone (2002) (18)
Prostate cancer in nonurological patients with normal prostates on digital rectal examination. (1992) (18)
Development and internal validation of preoperative transition zone prostate cancer nomogram. (2006) (18)
Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues (2019) (18)
Long‐term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence (2018) (18)
Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment (2017) (18)
Upregulation of centromere protein F is linked to aggressive prostate cancers (2018) (18)
Impact of prostate volume on oncologic, perioperative, and functional outcomes after radical prostatectomy (2015) (17)
[Immunotherapy of metastatic renal cell carcinoma in Germany. An assessment of the current status]. (2002) (17)
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. (2007) (17)
Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon α in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment (2005) (17)
High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer (2017) (17)
A proposal of a new nomogram for predicting upstaging in contemporary D’Amico low-risk prostate cancer patients (2017) (17)
High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer (2018) (17)
Results of radical prostatectomy in newly diagnosed prostate cancer: long-term survival rates in locally advanced and high-risk cancers. (2013) (17)
Assessment of rates of lymph nodes and lymph node metastases in periprostatic fat pads in a consecutive cohort treated with retropubic radical prostatectomy. (2012) (17)
Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy (2007) (16)
Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth. (1999) (16)
[Urologic complications after kidney transplantation. Experiences in a center with 539 recipients]. (1994) (16)
Low Other Cause Mortality Rates Reflect Good Patient Selection in Patients with Prostate Cancer Treated with Radical Prostatectomy. (2016) (16)
Detection and Characterization of Early Prostate Cancer by Six Systematic Biopsies and Fine Needle Aspiration Cytology in Prostates from Bladder Cancer Patients (2001) (16)
Transplantation of human renal cell carcinoma into NMRI nu/nu mice. III. Effect of irradiation on tumor acceptance and tumor growth. (1985) (16)
Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. (2017) (16)
Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladder. (1997) (16)
NeuroSAFE robot-assisted laparoscopic prostatectomy versus standard robot-assisted laparoscopic prostatectomy for men with localised prostate cancer (NeuroSAFE PROOF): protocol for a randomised controlled feasibility study (2019) (16)
Primary Gleason pattern upgrading in contemporary patients with D'Amico low‐risk prostate cancer: implications for future biomarkers and imaging modalities (2017) (15)
Surgical therapy for localized prostatic carcinoma (2005) (15)
PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer (2018) (15)
Radical prostatectomy in patients aged 75 years or older: review of the literature (2017) (15)
Treatment of Prostate Cancer—The Clinical Use of Radical Prostatectomy (2003) (15)
[Hyaluronic acid and hyaluronidase. 2 new bladder carcinoma markers]. (2001) (14)
Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer. (2008) (14)
Controversies in the management of localized prostate cancer: radical prostatectomy still the standard of care. (2012) (14)
Renal scarring after symptomatic and asymptomatic upper urinary tract infection: a prospective study. (1982) (14)
The Impact of Lymph Node Metastases Burden at Radical Prostatectomy. (2018) (14)
MR Imaging of Prostate Cancer: Diffusion Weighted Imaging and (3D) Hydrogen 1 (1H) MR Spectroscopy in Comparison with Histology (2010) (14)
The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy (2018) (14)
The value of urinary cytology, serum and urinary carcinoembryonic antigen, rheumatoid factors, and urinary immunoglobulin concentration as tumor markers or prognostic factors in predicting progression of superficial bladder cancer. (1983) (14)
Extracorporeal Shockwave Lithotripsy Compared with Ureteroscopy for the Removal of Small Distal Ureteral Stones (2004) (13)
Do serum C-reactive protein measurements help to discriminate episodes of renal dysfunction in patients after renal transplantation? (2001) (13)
[Functional results of various surgical techniques for radical prostatectomy]. (2003) (13)
Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer (2020) (13)
Anatomy and physiology of the male urethral sphincter and its preservation in prostatic surgery (1999) (13)
THE INFLUENCE OF AN ANGIOTENSIN II ANTAGONIST, SARALASIN, GIVEN BEFORE DONOR NEPHRECTOMY, ON KIDNEY FUNCTION AFTER TRANSPLANTATION: A Controlled prospective study (1983) (13)
Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. (2018) (13)
Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA (2017) (13)
Adherence of the indication to European Association of Urology guideline recommended pelvic lymph node dissection at a high-volume center: Differences between open and robot-assisted radical prostatectomy. (2015) (13)
„Expanded prostate cancer index composite“ (EPIC-26) (2015) (13)
Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients (2012) (13)
Complicated urinary tract infections. (1991) (12)
Expression of CCCTC‐binding factor (CTCF) is linked to poor prognosis in prostate cancer (2019) (12)
Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study (2018) (12)
Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy. (2020) (12)
Surgical anatomy of the prostate in the era of radical robotic prostatectomy (2011) (12)
Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes. (2018) (12)
Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer (2019) (12)
Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies. (2011) (12)
Epidemiology and statistical methods in prediction of patient outcome (2005) (12)
Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy (2017) (12)
Centralization and Quality Control of Elective Surgery Improve Outcome: Aren't We Ethically Obliged to Force the Pace of Creating High-volume Centers? (2015) (12)
Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma (1998) (11)
[Transrectal ultrasound-guided punch biopsies of the prostate. Indication, technique, results, and complications]. (2003) (11)
Reversibility of preglomerular active vasoconstriction in the first weeks after complete unilateral ureteral obstruction by inhibition of prostaglandin synthesis. (1983) (11)
Ratio free/total PSA (%f-PSA) in men with total PSA 0.5–3 ng/ml: improvement for prostate cancer detection? (2000) (11)
Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer (2004) (11)
Use of mitomycin as prophylaxis following endoscopic resection of superficial bladder cancer. (1986) (11)
[Ureterorenoscopy (URS) in treatment of ureteral calculi. I. Safety and effectiveness of URS as auxiliary treatment after ESWL]. (1999) (11)
Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. (2017) (11)
Advances in the management of high‐risk localised and metastatic prostate cancer (2012) (11)
Advancing Age and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men with Gleason Score 6 Prostate Cancer. (2019) (11)
Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram (2018) (11)
[The value of real-time elastography in the diagnosis of prostate cancer]. (2009) (10)
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer (2021) (10)
[Morphologic principles for radical prostatectomy]. (1991) (10)
Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. (2021) (10)
Reply to Juan Morote’s Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659–68 (2010) (10)
Predictors of short and long term urinary incontinence after radical prostatectomy in prostate MRI: Significance and reliability of standardized measurements. (2019) (10)
Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sum. (2008) (10)
Martini‐Klinik experience of prostate cancer surgery during the early phase of the COVID‐19 pandemic (2020) (10)
Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers (2020) (10)
A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma. (2000) (10)
Chemotherapy and human bladder carcinoma transplanted into NMRI nu/nu mice. (1985) (10)
NY‐ESO‐1 expression is tightly linked to TMPRSS2–ERG fusion in prostate cancer (2014) (10)
Cytostatic intravesical instillation in patients with superficial bladder carcinoma for the prevention of recurrent tumors. (1988) (10)
North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients (2018) (10)
Upregulation of PTTG1 is associated with poor prognosis in prostate cancer (2020) (9)
[Fast-track surgery in radical retropubic prostatectomy. First experiences with a comprehensive program to enhance postoperative convalescence]. (2005) (9)
Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair (2020) (9)
[Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy]. (2003) (9)
The absence of an allergic reaction to cyclosporine capsules in a patient allergic to standard oral and intravenous solutions of cyclosporine. (1988) (9)
Prediction of tumor heterogeneity in localized prostate cancer. (2002) (9)
Oncological, functional and perioperative outcomes in transplant patients after radical prostatectomy (2016) (9)
Detection of human telomerase RNA in the tumour‐surrounding mucosa of bladder carcinomas as a marker for premalignant transformation (2005) (9)
Adverse reaction to contrast material in a patient treated with local interleukin-2. (1992) (9)
Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. (2015) (9)
External validation of a preoperative nomogram for prediction of the risk of recurrence after radical prostatectomy. (2010) (9)
Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers. (2015) (9)
[Nerve-sparing radical retropubic prostatectomy. Results of a patient survey]. (2001) (8)
SNW1 is a prognostic biomarker in prostate cancer (2019) (8)
Effect of prostatic apex shape (Lee types) and urethral sphincter length in preoperative MRI on very early continence rates after radical prostatectomy (2021) (8)
The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer (2019) (8)
[Success rates of two-layer, microsurgical vasovasostomy. Results from a patient questionnaire and comparison with one-layer technique]. (2006) (8)
Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure. (1999) (8)
[Prognostic markers for prostate cancer]. (2000) (8)
Innovative treatment for clinically localized adenocarcinoma of the prostate: The future role of molecular imaging (1999) (8)
The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument against. (1996) (8)
[The diagnosis of prostatic carcinoma]. (1991) (8)
Impact of preoperative risk on metastatic progression and cancer‐specific mortality in patients with adverse pathology at radical prostatectomy (2017) (8)
Distribution of 486P 3/12 antigen, ABO(H) blood group antigen and T antigen in cystectomy specimens from patients with stage T2 transitional cell carcinoma of the bladder. (1992) (8)
Early clinical experience with water-jet dissection (hydro-jet) during nerve-sparing radical retropubic prostatectomy (2002) (8)
The role of C-reactive protein in graft dysfunction after renal transplantation. (1999) (8)
271: Long Term Prophylaxis with Mitomycin C (MMC) Further Reduces Tumor Recurrence Compared to Short Term Prophylaxis with MMC or Bacillus Calmette-Guerin (BCG) (2004) (7)
[Multilocular, giant angiomyolipoma of the kidney, adrenal gland and para-aortic lymph nodes. Case report of a 9-year-old boy with tuberous sclerosis]. (1994) (7)
[Diagnosis of localized prostate cancer: screening and preoperative staging]. (1991) (7)
IMPORTANCE OF BASELINE POTENCY RATE ASSESSMENT OF MEN DIAGNOSED WITH CLINICALLY LOCALIZED PROSTATE CANCER PRIOR TO RADICAL PROSTATECTOMY (2008) (7)
[DNA methylation on urinalysis and as a prognostic marker in urothelial cancer of the bladder]. (2007) (7)
101 THE VALUE OF THE PCA3 ASSAY IN GUIDING DECISION WHICH MEN WITH A NEGATIVE PROSTATE BIOPSY NEED IMMEDIATE REPEAT BIOPSY: PRELIMINARY EUROPEAN DATA (2007) (7)
Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups. (2020) (7)
The Role of Pelvic Lymph Node Dissection During Radical Prostatectomy in Patients With Gleason 6 Intermediate-risk Prostate Cancer. (2016) (7)
Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection. (2018) (7)
Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer (2019) (7)
Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer (2020) (7)
[DaVinci robot-assisted laparoscopic prostatectomy: benefit for obese men? - A matched-pair analysis]. (2015) (7)
[Surgical results of epididymovasostomy and vaso-vasostomy]. (1983) (6)
Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer (2021) (6)
[MR tomography in prostatic carcinoma: comparison of conventional and endorectal MRT]. (1994) (6)
Management of cytomegalovirus infection in high-risk recipients after renal transplantation: prophylaxis by hyperimmunoglobulins or DHPG treatment? (1993) (6)
Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer (2020) (6)
Prostatic Biopsy after Radiotherapy: When and How (2002) (6)
[Treatment of metastatic renal cell carcinoma. Value of immunotherapy compared with surgery of metastases]. (2000) (6)
Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer (2010) (6)
Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment (2019) (6)
[Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder]. (2008) (6)
aInternational Consortium for Health Outcomes Measurement (2015) (6)
Intratumoral depot interleukin-2 therapy inhibits tumor growth in Dunning adenocarcinoma of the prostate implanted subcutaneously in rats (1997) (6)
Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer. (2020) (6)
1496 TESTOSTERONE TREATMENT AFTER RADICAL PROSTATECTOMY FOR PATHOLOGICALLY ORGAN-CONFINED PROSTATE CANCER; RESULTS FROM A MULTI-INSTITUTIONAL STUDY (2010) (6)
[Nerve sparing retroperitoneal lymphadenectomy with intraoperative electrostimulation in patients with nonseminomatous testicular tumors]. (1992) (6)
Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence. (2020) (6)
Impact of the estimated blood loss during radical prostatectomy on functional outcomes. (2019) (6)
High RSF1 protein expression is an independent prognostic feature in prostate cancer (2020) (6)
Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy (2004) (6)
[Serum markers for early detection and staging of prostate cancer. Status report on current and future markers]. (2003) (6)
A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy (2020) (6)
Tumor characteristics, oncological and functional outcomes after radical prostatectomy in very young men ≤ 45 years of age (2019) (6)
Does increasing life expectancy affect competing mortality after radical prostatectomy? (2014) (6)
Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps. (2000) (6)
Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer. (2020) (6)
[Pathogenesis and therapy of rupture of the transplanted kidney. Experiences in 186 transplantations]. (2008) (5)
Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features (2021) (5)
[Preoperative assessment of tumor aggressiveness in localized prostatic carcinoma]. (1995) (5)
Detailed Quantification of High-grade Cancer Allows Precise Prediction of Prostate Cancer Prognosis. (2016) (5)
[Kidney donors and kidney transplantation in the elderly]. (2004) (5)
Pulsed-field gel electrophoresis for the analysis of Listeria monocytogenes infection clusters after kidney transplantation (2000) (5)
Upregulation of SPDEF is associated with poor prognosis in prostate cancer (2019) (5)
Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion (2020) (5)
[Active surveillance for prostate cancer]. (2008) (5)
In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors (2005) (5)
The Significance of Primary Biopsy Gleason 5 in Patients with Grade Group 5 Prostate Cancer. (2020) (5)
The impact of very high initial PSA on oncological outcomes after radical prostatectomy for clinically localized prostate cancer. (2020) (5)
Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI (2018) (5)
Re: Intraoperative nerve stimulation with measurement of urethral sphincter pressure changes during radical retropubic prostatectomy: a feasibility study. C. P. Nelson, J. E. Montie, E. J. McGuire, G. Wedemeyer and J.T. Wei. J Urol, 169: 2225-2228, 2003. (2004) (5)
Virus detection by DNA in situ hybridization in renal transplantation--a new perspective for differential diagnosis of virus infection versus rejection. (1990) (5)
Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients (2020) (5)
Differences in Patient Characteristics Among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice at a European High-Volume Center (2016) (5)
PREOPERATIVE DEGREE OF PATIENT INFORMATION INFLUENCES SATISFACTION WITH TREATMENT STRONGER THAN FUNCTIONAL ASPECTS IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY (2008) (4)
Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis (2018) (4)
VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy (2015) (4)
PCA3 REPRESENTS A CLINICALLY MEANINGFUL PREDICTOR OF PROSTATE CANCER AT REPEAT BIOPSY (2008) (4)
PERFORMANCE ANALYSIS OF DIFFERENT PCA3 CUT-OFFS (2008) (4)
[Cystectomy for indications other than bladder cancer]. (2004) (4)
Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study. (2020) (4)
Tumor heterogeneity of renal cell carcinoma. (1990) (4)
[Side-fire laser coagulation of the prostate with the neodymium:YAG-laser. Long-term outcome]. (2001) (4)
Treatment of Patients with Metastatic Renal Cell Carcinoma: Results of Two Clinical Phase II Studies with Alpha-2-Interferon Versus Alpha-2-Interferon Plus Vinblastine or Gamma Interferon in 55 Patients (1987) (4)
A matched-pair analysis between radical prostatectomy and low dose rate brachytherapy in low risk prostate cancer patients (2008) (4)
High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. (2020) (4)
EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY MEMBERS (EGFR AND HER2) ARE PROGNOSTIC MARKERS AND POTENTIAL THERAPEUTIC TARGETS IN PROSTATE CANCER (2006) (4)
The case against extended lymph-node dissection for prostate cancer (2006) (4)
Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion‐positive prostate cancers (2020) (4)
[Therapeutic options in hormone refractory prostate carcinoma]. (2000) (4)
Experience with water-jet dissection in nerve sparing radical prostatectomy (NSRRP) (2002) (4)
Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers (2020) (4)
258Prediction of side specific extracapsular extension at radical prostatectomy in European patients: Accuracy of a novel, internally validated logistic regression-based nomogram vs. tree structured regression analysis (2005) (4)
FEASIBILITY OF PROSTATE CANCER DETECTION BY TRIPLE SPECTROSCOPY (2008) (4)
[Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer]. (1994) (4)
Long‐term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life‐table data (2021) (4)
The effectivity and morbidity of URS as auxiliary therapy after ESWL (1999) (4)
[Ureterorenoscopy (URS) in treatment of ureteral calculi. II. Ureteroscopic treatment of calculus debris after ESWL]. (1999) (4)
LONG-TERM TUMOR CONTROL WITH INHALATIONAL INTERLEUKIN 2 THERAPY IN CARDIAC HIGH RISK PATIENTS WITH METASTATIC RENAL CARCINOMA (2008) (4)
Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death (2022) (4)
Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets (2021) (4)
Prostate‐specific antigen levels of ≤4 and >4 ng/mL and risk of prostate cancer‐specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer (2021) (4)
Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer (2020) (4)
PROSTATE CANCER CHARACTERISTICS OF POTENTIAL CANDIDATES FOR ACTIVE SURVEILLANCE AFTER INITIAL AND REPEAT BIOPSY (2008) (4)
CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo (2021) (4)
[Erectile dysfunction and hypogonadism. Is routine endocrine screening necessary?]. (1994) (4)
Identification of virus DNA in kidney transplants by fine-needle aspiration biopsy. (1988) (4)
[Regional immunotherapy of metastatic renal cell carcinoma]. (2002) (4)
Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy. (2019) (3)
Loss of CCAAT‐enhancer‐binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers (2018) (3)
Consecutive selective aspiration cytology of renal cortex and renal medulla in kidney transplants. (1988) (3)
The operable renal cell carcinoma: summary and conclusions. (1990) (3)
Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy (2019) (3)
Xenogenic transplantation of human bladder- and renal-cell carcinoma into NMRI mice treated with cyclosporin A and into NMRI nu/nu mice. Introduction of a new experimental cancer model. (1987) (3)
630The new proteomic-based point-of-care (POC) urine NMP22-bladder.chek® compared to the standard NMP22-elisa urine lab test for bladder cancer detection (2005) (3)
[Metaphylaxis of urinary calculi]. (1997) (3)
[Tumor markers and prognostic parameters in urinary bladder cancer]. (1990) (3)
High mitochondria content is associated with prostate cancer disease progression (2013) (3)
Unilateral medullary sponge kidney: cause of persistent bacteriuria. (1976) (3)
Prevalence of a tertiary Gleason grade and its association to adverse histopathological features in a contemporary consecutive prostatectomy series (2008) (3)
Bacterial localization in patients with end stage renal disease to avoid bilateral nephrectomy before renal transplantation. (1983) (3)
Is a Prediction of Negative Margins and Continence Possible before Radical Prostatectomy (1995) (3)
1366 ASSESSMENT OF MORTALITY FOR NON CANCER-RELATED MORTALITY IN PATIENTS WITH HISTOLOGICALLY PROVEN SMALL RENAL MASSES MANAGED NON-SURGICALLY (2010) (3)
Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes (2018) (3)
EVALUATION OF PROSTATE CANCER DETECTION WITH REAL- TIME-ELASTOGRAPHY: A COMPARISON WITH STEP SECTION PATHOLOGICAL ANALYSIS AFTER RADICAL PROSTATECTOMY (2008) (3)
Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy? (2012) (3)
Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy1 (2019) (3)
Investigation on the occurrence of lymphoceles after allogeneic kidney transplantation and therapy (1997) (3)
Association of Age With Risk of Adverse Pathological Findings at Radical Prostatectomy in Men With Gleason Score 6 Prostate Cancer (2020) (3)
Urodynamic changes after radical prostatectomy (1997) (3)
Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion (2019) (3)
The impact of anxiety and depression on surgical and functional outcomes in patients who underwent radical prostatectomy (2018) (3)
Human transitional cell carcinoma in the NMRI-nu/nu mouse bladder: a new animal model for the in vivo use of monoclonal antibodies and cytotoxic agents. (1986) (3)
Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer (2018) (3)
PCA3 SCORE BASED NOMOGRAM TO PREDICT LOW-VOLUME/LOW-GRADE PROSTATE CANCER IN RADICAL PROSTATECTOMY SPECIMENS (2009) (3)
Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions (2020) (3)
p53 in noncancerous bladder mucosa as a marker of disease recurrence in patients with superficial transitional cell carcinoma of the bladder. (1997) (3)
Supersensitive detection of prostate-specific antigen in lyophilisation-concentrated serum. (1996) (3)
Prostate Cancer: Staging IPD15-10 SIZE AND EXTENSION OF LYMPH NODE METASTASES IN PROSTATE CANCER PATIENTS: IMPLICATIONS FOR RADIOLOGICAL IMAGING BASED ON 6804 LYMPH NODES (2014) (3)
High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases (2018) (3)
[Treatment of rectal injuries with vesicorectal fistulization in radical prostatectomy]. (1995) (3)
PROSTATE CANCER DETECTION RATE IN PATIENTS WITH LOW SERUM PROSTATE SPECIFIC ANTIGEN AND NORMAL DIGITAL RECTAL EXAMINATION IN A EUROPEAN REFERRAL POPULATION (2006) (3)
[Anatomy and sonography of the prostate]. (1989) (3)
[Experiences with local collagen injection in male stress incontinence]. (1997) (3)
A comparison of two preoperative nomogram predicting recurrence following radical prostatectomy (2002) (3)
Dyeing: a simple method for detecting positive or negative surgical margins. (1995) (3)
Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence (2020) (2)
A positive surgical margin following radical prostatectomy should not routinely be the indication for adjuvant radiation therapy. (2014) (2)
[Ambulatory carboplatin monotherapy in advanced seminoma]. (1990) (2)
Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer (2020) (2)
[Value of determining prostate-specific antigen for early detection or prostatic carcinoma]. (1995) (2)
Re: A comparison of ureteroscopy to in situ extracorporeal shock wave lithotripsy for the treatment of distal ureteral calculi. (1999) (2)
[Early complications of radical prostatectomy. Pelvic vein compression caused by wound drainage]. (1994) (2)
Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer (2004) (2)
Impact of surgeon-defined capsular incision during radical prostatectomy on biochemical recurrence rates (2016) (2)
Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy. (2021) (2)
Long-term monitoring of 486P 3/12 antigen pattern (quantitative immunocytology) before, during, and after mitomycin C prophylaxis in patients with superficial bladder cancer. (1995) (2)
Treatment of acute cellular rejection in renal transplantation patients on ciclosporin with antithymocyte globulin. (1988) (2)
[Can recurrent urinary tracts infections with existing vesicoureteral reflux be checked (author's transl)]. (1978) (2)
Immunocytologic staining of cytokeratin in bone marrow aspirates to detect micrometastatic cells fails in patients with metastatic urologic carcinoma. (1997) (2)
Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers (2019) (2)
[Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12]. (2003) (2)
Analysis of T-Cell Subsets and DNA In-Situ-Hybridization — A New Diagnostic Tool for Virus Infections in Kidney Transplants (1987) (2)
Nierentransplantation in der Urologie (2006) (2)
MULTIVARIATE ANALYSIS OF PREOPERATIVE PARAMETERS FOR PREDICTION OF EARLY PSA RELAPSE AFTER RADICAL PROSTATECTOMY (RP) (1999) (2)
High concordance of findings obtained from transgluteal magnetic resonance imaging ‐ and transrectal ultrasonography‐guided biopsy as compared with prostatectomy specimens (2017) (2)
[Technique of nerve-sparing radical retropubic prostatectomy]. (2004) (2)
551 Validation of biopsy-based pathological algorithm to predict lymph node metastases in clinically localized prostate cancer (PCA): impact on changing treatment modalities (2004) (2)
[Development of tumor selection based on pathological stage in clinically localized prostate carcinoma]. (1998) (2)
Survival benefit of local vs. no local treatment for metastatic prostate cancer - impact of baseline PSA and metastatic substages (2018) (2)
[Metachronous or contralateral adrenal metastases in renal cell cancer]. (1993) (2)
Experimental studies on the heterogeneity of bladder carcinoma. (1988) (2)
[Long-term results of Stamey bladder neck suspension. Effect of data analysis technique on surgical result]. (1997) (2)
[The susceptibility to urinary tract infections after antireflux operations (author's transl)]. (1978) (2)
[Occurrence of lymphoceles after allogeneic kidney transplantation and their therapy]. (1997) (2)
Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. (2019) (2)
Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy. (2000) (2)
THE VALUE OF THE PCA3 SCORE IN GUIDING PROSTATE BIOPSY DECISION IN MEN WITH A PRIOR NEGATIVE BIOPSY (2008) (2)
1260: Age-And Percent Free PSA Stratified Risk Analysis for Prostate Cancer Detection in Men with a Total Serum PSA 2-4NG/ML and Benign Digital Rectal Examination (2004) (2)
290: Reduction of Early Tumor Recurrences in pTa/pT1 Bladder Carcinoma Using an Extended Resection Protocol (2004) (2)
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer (2019) (2)
High risk patients with pulmonary metastases of renal cell carcinoma: Safety and efficacy of inhaled interleukin-2 (IL-2) compared to systemic IL-2 (2003) (2)
[Indications for and results of radical prostatectomy]. (2003) (2)
EXPRESSION OF TRANSFORMING GROWTH FACTOR-BETA 1 DEPENDS ON THE DEGREE OF PARTIAL URETERAL OBSTRUCTION (1999) (2)
Does internal urethrotomy influence susceptibility to recurrent urinary tract infection? (1982) (2)
Treatment of localized prostate cancer (2007) (2)
[Diagnosis of bladder calculi]. (1997) (2)
[Stress incontinence in the female--a urologic disease]. (1983) (2)
[Incidental detection of renal cell cancer]. (1992) (2)
[What is the value of radical prostatectomy in lymph node positive prostate carcinoma?]. (1998) (2)
Percentage of free PSA (%FPSA) is not an independent predictor of pathologic stage or psa recurrence in patients with localised prostate cancer treated with Radical Prostatectomy (RP) (2002) (2)
Prostate cancer suppresses dendropoiesis both in vitro and in vivo (2002) (1)
[Techniques for interventional and operative therapy of calculi]. (1997) (1)
[Postoperative function and aspects of the quality of life after Schröder-Essed technique of penile straightening]. (2000) (1)
971 THE EFFECT OF BODY MASS INDEX ON HISTOPATHOLOGICAL PARAMETERS; RESULTS OF A LARGE EUROPEAN CONTEMPORARY CONSECUTIVE OPEN RADICAL PROSTATECTOMY SERIES (2009) (1)
Clinical stage T2 prostate cancer treated with radical prostatectomy has similar outcome across its substages (2002) (1)
Reinvestigation of patients after primary therapy of testicular tumor. (1997) (1)
[Isoforms of free prostate-specific antigen]. (2004) (1)
584: PSA-Induced Inhibition of Dendropoiesis in Prostate Cancer (2004) (1)
Does low-risk prostate cancer detection change with repeat biopsies? (2012) (1)
47: Comparison of Urinary Diversion Outcome Concerning the Ureteral Anastomosis for Bladder Cancer with the Leduc Tunnel and the Chimney Technique (2004) (1)
963: Number of Lymph Nodes Removed and Examined and the Continent of Origin Represent the Foremost Predictors of Lymph Node Invasion in Men with Clinically Localized Prostate Cancer (2006) (1)
MP83-16 HETEROGENEITY IN D'AMICO LOW-RISK PROSTATE CANCER: DIFFERENCES IN UPGRADING AND UPSTAGING ACCORDING TO ACTIVE SURVEILLANCE ELIGIBILITY (2015) (1)
Consensus Report, 1987 (1987) (1)
Abstract 572: Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG fusion positive, PTEN deleted prostate cancers (2014) (1)
Do impalpable prostate cancers not visible on transrectal ultrasound differ from those visible (2003) (1)
Toxicity in a multimodality approach of radical prostatectomy with radiation and hormonal therapy. (2016) (1)
792 COMPARISON BETWEEN COMPLICATION RATES LENGTH OF STAY AND COSTS OF MINIMAL INVASIVE VS. OPEN RADICAL PROSTATECTOMY (2010) (1)
890: Erection, Potency, and Sexual Intercourse Following Unilateral Nerve Sparing Prostatectomy with N. Suralis Transplantation Contralateral Compared to Nerve Sparing Prostatectomy. A Critical Analysis of Preoperativ Potent Men (2004) (1)
Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan‐confined prostate cancer (2022) (1)
MP82-05 A COMPARISON OF DIFFERENT TREATMENT OPTIONS FOR LYMPH NODE-POSITIVE PROSTATE CANCER AT RADICAL PROSTATECTOMY (2015) (1)
HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN) ON INITIAL PROSTATE BIOPSY IS NOT A RISK FACTOR FOR PROSTATE CANCER AT REPEAT BIOPSY (2009) (1)
52 Show prostate cancers located in the transition zone a more favourable outcome following radical prostatectomy than tumours of the peripheral zone (2004) (1)
262: Nomograms for Bladder Cancer Recurrence According to Grade and Stage (2004) (1)
112 ACCURACY OF PERCENT FREE PSA TO PREDICT PROSTATE CANCER DIAGNOSIS IN MEN WITH TOTAL PSA RANGES LOWER THAN 2.5 NG/ML (2007) (1)
[Systematic analysis of treatment results as a quality control instrument using the example of a large European center]. (2015) (1)
ABSTRACTS (pp 173–235) (2003) (1)
Diagnostic value of the immunocyt test detecting urothelial cell carcinoma of the bladder (2003) (1)
1026 Development and internal validation of nomograms predicting insignificant prostate cancer (IPCA) and tumour volume (TV) at radical prostatectomy (RP) (2005) (1)
Are false positive urine tests in the diagnosis of bladder cancer really wrong - or do they predict tumour recurrence? (2002) (1)
Analysis of fertility in patients with stage 1 non-seminomatous germ-cell tumours (NSGCT). The German prospective multicenter trial (2003) (1)
684 BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: A CASE OF MULTIPLICATIVE INTERACTION BETWEEN SURGICAL MARGIN STATUS AND PATHOLOGICAL STAGE (2010) (1)
Does low-risk prostate cancer detection change with repeat biopsies? (2012) (1)
289 Long-time survival (>4 yrs) in non resectable pulmonary metastatic renal cell carcinoma and aerosol interleukin-2 therapy (2004) (1)
A COMPARISON OF 2 MODES OF ADMINISTRATION OF RECOMBINANT INTERLEUKIN 2: INHALATIVE VERSUS SYSTEMIC THERAPY (1999) (1)
Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages - Does extent of tumor involvement matter? (2020) (1)
Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer. (2023) (1)
Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladder (2005) (1)
A validated strategy to select patients for a nerve-sparing radical prostatectomy (2000) (1)
NOT ALL HIGH RISK PROSTATE CANCER PATIENTS HAVE THE SAME RISK OF BIOCHEMICAL RECURRENCE AFTER SURGERY. A MULTI-INSTITUTIONAL ANALYSIS OF PREDICTORS OF GOOD OUTCOME (2009) (1)
[Quality criteria in urology : How to obtain comparable results?] (2021) (1)
PROSTATE CANCER 3 (PCA3) REPRESENTS A CLINICALLY MEANINGFUL PREDICTOR OF PROSTATE CANCER AT REPEAT BIOPSY (2008) (1)
[Technical aspects of nerve sparing during retropubic prostatectomy]. (2007) (1)
Advancing age and the risk of adverse pathology at radical prostatectomy in men with biopsy Gleason score 6 prostate cancer. (2020) (1)
Advancing Age and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men with Gleason Score 6 Prostate Cancer (2019) (1)
Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors? (1999) (1)
474: Prostate Specific Antigen (PSA) vs. Cancer Volume and High-Grade Cancer (PCA) Volume at Radical Prostatectomy (RP) in a Large European Cohort: Is the PSA Era Over in Europe as Well? (2005) (1)
752 ADJUVANT RADIOTHERAPY HAS NO IMPACT ON BIOCHEMICAL RECURRENCE FREE SURVIVAL IN PROSTATE CANCER PATIENTS WITH SEMINAL VESICLES INVASION TREATED WITH RADICAL PROSTATECTOMY (2009) (1)
Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146 (2002) (1)
[Morphologic results of 106 consecutive radical prostatectomy specimen of patients with clinical stage B1-B3 (T2a-c) and histologically negative lymph nodes in the fossa obturatoria]. (1994) (1)
[The bladder neck suspension according to Stamey-Pereyra for stress urinary incontinence (author's transl)]. (1981) (1)
Prostate cancer detection by laser induced autofluorescence and multicomponent spectroscopy (2007) (1)
Association of very low PSA with increased metastases and death in patients with biopsy Gleason score 8-10 prostate cancer (2020) (1)
[Individualized therapy with alpha-interferon in metastatic renal cell carcinoma]. (1995) (1)
1491: Measurements of Urokinase Receptor Fractions and Human Glandular Kallikrein 2 in Serum Improves Discrimination of Men with Prostate Cancer from Men with no Evidence of Malignant Disease (2005) (1)
321: No Differences in Biochemical Recurrence between NO and NX Patients Subjected to Radical Prostatectomy: A Matched Analyses on 5977 Patients (2007) (1)
[18F]FLUOROCHOLINE COMBINED IN-LINE PET-CT SCAN FOR DETECTION OF LYMPH-NODE METASTASIS PRIOR TO RADICAL PROSTATECTOMY: RESULTS FROM A PROSPECTIVE HISTOLOGY BASED STUDY (2008) (1)
Histopathological results of radical prostatectomy specimen of men younger than 50 years of age at the time of surgery: possible implications for prostate cancer screening programs? (2023) (1)
[Cytomegalovirus diseases following allogenic kidney transplantation]. (1992) (1)
PD14-01 PREVENTION OF PELVIC LYMPHOCELES AFTER RADICAL RETROPUBIC PROSTATECTOMY BY USING A POLYSACCHARIDE HEMOSTAT - FIRST RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL (2014) (1)
389: Validation of the Epstein Criteria for Insignificant Prostate Cancer in European men (2007) (1)
1585: Prevalence and Prognostic Significance of a Tertiary Gleason Pattern in Radical Prostatectomy Specimens Among a Cohort of 3147 Consecutive Prostate Cancer Patients (2006) (1)
690 PROSTATE CANCER ANTIGEN 3 (PCA3) IS AN INDEPENDENT AND SIGNIFICANT PREDICTOR FOR PATHOLOGICALLY INSIGNIFICANT PROSTATE CANCER (PCA) IN MEN UNDERGOING RADICAL PROSTATECTOMY (2009) (1)
Development of Technologic Solutions to Address Complex Local Requirements of an International Prostate Cancer Clinical Quality Registry. (2019) (1)
Frequency and Extent of High-Grade Prostatic Intraepithelial Neoplasia in Cystoprostatectomy Specimens (2000) (1)
Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram (2018) (1)
IMPORTANCE OF BASELINE POTENCY RATE ASSESSMENT OF MEN DIAGNOSED WITH CLINICALLY LOCALISED PROSTATE CANCER PRIOR TO RADICAL PROSTATECTOMY (2008) (1)
[Plasma TGF-beta1 concentrations in patients with prostate carcinoma or benign prostatic hyperplasia]. (1998) (1)
Treatment of Bladder Exstrophy and Epispadias (1999) (1)
722 Size and extension of lymph node metastases in prostate cancer patients: Implications for radiological imaging based on 6804 lymph nodes (2014) (1)
MICROVESSEL DENSITY IS SIGNIFICANTLY ASSOCIATED WITH PATHOLOGIC STAGE, GLEASON SCORE AND BIOCHEMICAL RECURRENCE IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER UNDERGOING RADICAL RETROPUBIC PROSTATECTOMY (2008) (1)
A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer (2019) (1)
Expression of immunoregulatory molecules on tubular cells and lymphocytes in fine-needle aspiration biopsy: early diagnostic marker for renal allograft rejection. (1988) (1)
1023 Impact of a polysaccharide hemostat on bleeding complications and pelvic lymphocele rates after radical prostatectomy: Initial results of a prospective randomized trial (2013) (1)
[Transurethral laser therapy of benign prostatic hyperplasia]. (1995) (1)
Results of conformal radiotherapy for local recurrences after Radical Prostatectomy (RP) (2002) (1)
MP18-15 A MODEL BASED ON FOUR KALLIKREIN MARKERS IN BLOOD IMPROVES THE PREDICTIVE ACCURACY OF ADVERSE PATHOLOGY AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2019) (1)
[Pathogenic mechanism, morphology, diagnosis and therapy of the rejection of the transplanted kidney]. (1982) (1)
Effect of study methodology on long-term outcome of the Stamey bladder neck suspension procedure (1997) (1)
[The bilateral nephrectomy in terminal renal disease (author's transl)]. (1978) (1)
Effect of adjuvant and salvage radiotherapy after radical prostatectomy on urinary continence. (2014) (1)
Nerve-sparing procedure (NS) during radical prostatectomy (RP): A risk factor for biochemical failure? (2003) (1)
Upregulation of transforming growth factor beta I receptors contributes to hydronephrotic atrophy in complete but not in partial ureteral obstruction (2002) (1)
Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. (2021) (1)
81 Differential gene expression in noncancerous prostate tissue of men with and without prostate cancer (2005) (1)
Quantitative Immunocytology with Monoclonal Antibody (MAB) 486 p 3/12: Clinical Application (1993) (1)
THE IMPACT OF ANXIETY AND DEPRESSION ON FUNCTIONAL OUTCOME IN PATIENTS WHO UNDERWENT RADICAL PROSTATECTOMY: PD51‐04 (2017) (1)
Intravesical Therapy for Superficial Bladder Carcinoma (1999) (1)
Aspiration cytology of liver transplants. (1988) (1)
836: Long Term Prophylaxis with Mitomycin C (MMC) Significantly Reduces Tumor Recurrence Compared to Short Term Prophylaxis with MMC or Bacillus Calmette-Guerin (BCG) In Non Muscle-Invasive Bladder Cancer (NMIBC) (2006) (1)
Increased urinary concentrations of monocyte chemoattractant protein-I (MCP-1) in children with progressive hydronephrotic damage (2002) (1)
Tumor infiltrating dendritic cells (DC) in prostate cancer (PCa): Implications for vaccine therapy (2005) (1)
10-year experience of robot-assisted radical prostatectomy: the road from cherry picking to standard procedure. (2016) (1)
SIGNIFICANCE OF PSA INTER-ASSAY VARIABILITY ON CLINICAL PROSTATE CANCER DETECTION-AIDS (2008) (1)
[Is rehabilitation of erectile function following pelvic surgery reasonable? Review of the literature: from sports to PDE5 inhibitors]. (2008) (1)
1023: The Role of Digital Rectal Examination in Prediction of Pathological Stage After Radical Prostatectomy in Contemporary Patients (2007) (1)
[Status of PSA determination for early detection of prostate carcinoma]. (1995) (1)
Side-by-side comparison of bladder cancer tests in a multi-center study (2003) (1)
Assessment of clinical and pathologic characteristics predisposing to biochemical disease recurrence following Radical Prostatectomy (RP) in men with pathologically organ confined prostate cancer (PCA) (2002) (1)
IS EXTENDED PELVIC LYMPH NODE DISSECTION JUSTIFIED IN PATIENTS WITH LOW RISK PROSTATE CANCER (2008) (1)
Long-term serial transplantation of different human bladder carcinomas into NMRI nu/nu mice. Histologic, flow cytometric and growth studies. (1987) (1)
[Pyelonephritic scar formation]. (1986) (1)
Immunocytology as a possible marker to identify patients who require prophylaxis. (1993) (1)
IS IT NECESSARY TO DIAGNOSE PROSTATE CANCER WITH A PROSTATE SPECIFIC ANTIGEN (PSA) OF < 4.0 NG/ML? (1999) (1)
359 TMS-1 is frequently hypermethylated in prostate cancer and can be re-induced by treatment with 5-aza-2-deoxycytidine (2004) (0)
863 LONG-TERM SURVIVAL WITH INHALATIONAL IL-2 THERAPY IN CARDIAC HIGH RISK PATIENTS WITH METASTATIC RENAL CARCINOMA (2007) (0)
Editorial comment on: Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. (2009) (0)
ADVANCED AGE PREDISPOSES TO HIGHER RATE OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2008) (0)
1888: Digital Rectal Examination is an Independent Predictor of Pathologic Gleason 7-10 in Patients Diagnosed with Extended Biopsy Schemes and Treated with Radical Prostatectomy (2007) (0)
4007 POSTER Molecular and functional profiling for an improved clinical management of prostate cancer (2007) (0)
171 Use of proerectile medication (PDE5-I) is an independent risk factor for PSA recurrence following radical prostatectomy (2014) (0)
MP11-20 OTHER MALIGNANCIES PRIOR PROSTATE CANCER DIAGNOSIS – CLINICAL OUTCOME AFTER RADICAL PROSTATECTOMY (2018) (0)
360 SAFE-R: A NOVEL SCORE, ACCOUNTING FOR ONCOLOGICAL SAFE NERVE-SPARING (2013) (0)
Outcome of multimodality treatment of high-risk localized prostate cancer (cT3-4 OR PSA >= 20 ng/ml OR biopsy Gleason score >= 8) with radical prostatectomy as initial step: a multi-institutional outcome study of 1413 patients (2009) (0)
661 A novel comprehensive complication index by Clavien in patients with radical prostatectomy (2015) (0)
MP-19.14: Three year follow-up of a multicenter trial comparing mitomycin C (MMC) long term with short-term treatment with MMC or Bacillus Calmette-Guerin (BCG) in non muscle-invasive bladder cancer (NMIBC) (2007) (0)
CANCER SPECIFIC AND OVERALL SURVIVAL IN PATIENTS WITH ORGAN CONFINED PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY (2008) (0)
187 PRE-OPERATIVE URINARY PROSTATE CANCER GENE 3 (PCA3) IS PREDICTING PATHOLOGICALLY CONFIRMED SMALL VOLUME AND INSIGNIFICANT PROSTATE CANCER (2011) (0)
GLEASON SCORE UPGRADING AT TIME OF PATHOLOGICAL GLEASON SCORE OCCURS MORE FREQUENTLY IN EXTERNAL BASED BIOPSIES THAN IN UNIVERSITY-BASED BIOPSIES (2006) (0)
991 THE RATE OF ADVERSE DISEASE AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY IN PATIENTS ELIGIBLE FOR ACTIVE SURVEILLANCE (2012) (0)
1306 PERIPROSTATIC FAT PADS HARBOR LYMPH NODES AND LYMPH NODE METASTASES: IMPACT ON PATHOLOGICAL WORK UP (2011) (0)
970: Dual Role of CEACAM1 in Angiogenesis and Invasion of Human Urinary Bladder Cancer (2004) (0)
REGION SPECIFIC LOCALIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND ITS RECEPTORS KDR AND FLT-1 IN HUMAN PROSTATE CARCINOMA (1999) (0)
THE EFFECT OF TISSUE ISCHAEMIA ON GENE EXPRESSION IN PROSTATE CANCER (2006) (0)
1348 THE IMPACT OF 3 WEEK CLINICAL REHABILITATION PROGRAM AFTER RADICAL PROSTATECTOMY ON EARLY CONTINENCE STATUS (2013) (0)
1204: Nerve Distribution along Prostatic Capsule (2006) (0)
689 PATIENTS WITH LOW RISK FEATURES, OMITTED PELVIC LYMPH NODE DISSECTION (PLND) BUT PATHOLOGICALLY LOCALLY ADVANCED PROSTATE CANCERS (PT3A/PT3BNX) HAVE A BETTER ONCOLOGICAL OUTCOME THAN THEIR PT3A/PT3B PN0-COUNTERPARTS (2012) (0)
212 Frequent methylation of apoptosis-associated genes in bladder cancer cell lines, tumour samples, and urine samples for diagnosis of bladder cancer (2004) (0)
FUNCTIONAL OUTCOMES AND QUALITY OF LIFE AFTER RADICAL PROSTATECTOMY: PATIENT REPORTED OUTCOMES OF A TERTIARY HIGH‐VOLUME CENTER: PD10‐04 (2017) (0)
987 CRITICAL ASSESSMENT OF URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF AGGRESSIVE PROSTATE CANCER (GLEASON SCORE ≥ 7) AT BIOPSY (2011) (0)
Abstract 5019: Impact of the ERG status on the prognostic relevance of prostate cancer biomarkers: a survey of 13,000 patients (2016) (0)
390: Durable Cancer Control in High Risk Prostate Cancer Patients Treated with Radical Prostatectomy (2007) (0)
NUCLEAR FACTOR-κB CYTOPLASMATIC STAINING INTENSITY IS AN INDEPENDENT PREDICTOR OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER (2009) (0)
PROSTATE CANCER DETETCTION RATE AT TOTAL PSA- LEVELS BELOW 2.5ng/ml: THE UTILITY OF PERCENT FREE PSA, MEANINGFUL %fPSA CUTOFFS AND THE CLINICAL SIGNIFICANCE OF PROSTATE CANCERS DETECTED (2008) (0)
Abstract 3809: TMPRSS2-ERG gene fusion is strongly associated with elevated androgen receptor expression in early prostate cancer (2011) (0)
873 A tertiary Gleason pattern at radical prostatectomy is associated with adverse histopathological features (2012) (0)
797 RISK ASSESSMENT FOR PROSTATE CANCER METASTASES BY USING THE CAPRA SCORE: RESULTS FROM 3209 EUROPEAN PATIENTS (2011) (0)
1030 EARLY RECURRENCES AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER: CAN WE IDENTIFY THOSE PATIENTS? (2007) (0)
95 THE PTEN-PATHWAY IN PROSTATE CANCER: ALTERATIONS AT SEVERAL KEY-POINTS DURING MALIGNANT TRANSFORMATION (2007) (0)
677: Influence of the Body Mass Index on Postoperative Continence and Potency after Radical Prostatectomy (2006) (0)
889: Predictive Accuracy, Sensitivity, and Specificity of Nuclear Matrix Protein 22 and Urine Cytology for Prediction of Recurrence of Non-Transitional Cell Carcinoma of the Bladder (2006) (0)
The Operable Renal Cell Carcinoma: Progress in Basic Research, Diagnosis, Surgical and Medical Therapy Heinrich Warner Stiftung, 3rd Symposium, Hamburg, November 1989 (1990) (0)
PREVALENCE AND PROGNOSTIC SIGNIFICANCE OF A TERTIARY GLEASON PATTERN IN RADICAL PROSTATECTOMY SPECIMENS AMONG A CONSECUTIVE COHORT OF 3147 PROSTATE CANCER PATIENTS (2006) (0)
Editorial Comment: Up-Front Intravesical Chemotherapy for Low Stage, Low Grade Recurrent Bladder Cancer (1996) (0)
349: Erection, Potency, Continence, and QOL in Patients Scheduled for Retropubic Prostatectomy. Is There a Preoperative Problem? Analysis of Patients with Validated Questionnaires (IIEFS, QLQ-C30, ICS-BPH SF) (2006) (0)
MP83-05 THE EFFECT OF NERVE-SPARING ON URINARY CONTINENCE AFTER RADICAL PROSTATECTOMY: IS IT THE PRESERVATION OF THE NEUROVASCULAR BUNDLES OR THE SURGICAL TECHNIQUE WHICH LEADS TO IMPROVED CONTINENCE RATES? (2015) (0)
1645: A Comparison of the 10 Most Frequently Used Nomograms for the Prediction of Insignificant Prostate Carcinoma (2006) (0)
826 Methylation of the E-cadherin and the TIMP-3 genes are positive prognostic markers for patients with non-muscle invasive bladder carcinoma (2004) (0)
Outcome of Multimodality Treatment of Clinically Locally Advanced Prostate Cancer With Radical Prostatectomy As Initial Step: a Multi-institutional Outcome Study of 895 Patients (2009) (0)
Correlation of molecular PSA subfractions with volume of benign and malignant prostate cancer tissue (2003) (0)
265: Effect of Autologous Blood Transfusion on Predictive Accuracy of Biochemical Recurrence after Radical Prostatectomy (2006) (0)
VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS UNDERGOING OPEN AND MINIMALLY INVASIVE RADICAL PROSTATECTOMY: POPULATION‐BASED TIME TREND ANALYSIS: MP97‐09 (2017) (0)
Oncological and functional outcome after radical prostatectomy in men ≤45 years of age (2017) (0)
STATE‐OF‐THE‐ART AUTOMATED EXTRACTION OF DETAILED PATHOLOGICAL DATA FROM NARRATIVELY WRITTEN ELECTRONIC HEALTH RECORDS: MP70‐01 (2018) (0)
MP22-12 ONCOLOGICAL OUTCOMES IN PATIENTS WITH HIGH LYMPH NODE BURDEN AFTER RADICAL PROSTATECTOMY (2019) (0)
484 COMPARISON OF METHYLATION PATTERNS BETWEEN PRIMARY AND RECURRENT NON-MUSCLE INVASIVE BLADDER CANCER (2007) (0)
1040 PRE-OPERATIVE URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF SMALL TUMOR VOLUME, INSIGNIFICANT, LOCALLY ADVANCED AND AGGRESSIVE PROSTATE CANCER (2011) (0)
157 High rates of significant prostate cancer are detectable in repeat biopsies (2012) (0)
23 Is the predictive accuracy of the 1997, 2001 partin tables, the preoperative as well as the postoperative nomograms affected by temporal stage migration in European patients? (2005) (0)
The clinical significance of NMRI NU/NU mice tumor model. (1982) (0)
564: Clinicians Can Accurately Select Patients in Whom Lymphadenectomy may be Safely Omitted at Radical Prostatectomy (2007) (0)
Prophylactic Antibiotics for Urological Procedures (1999) (0)
742 Only NeuroSAFE biopsy technique is suitable to assess positive surgical margins during nerve sparing radical prostatectomy compared to small biopsies taken from different locations of the neurovascular bundle (2014) (0)
IMPACT OF SAMPLING DENSITY ON INITIAL 10 OR MORE (+) CORE PROSTATE BIOPSY: DEVELOPMENT AND INTERNAL VALIDATION OF A 10+ CORES BIOPSY NOMOGRAM (2006) (0)
MP83-15 THE IMPACT OF NOT DETERMINABLE SURGICAL MARGINS AFTER RADICAL PROSTATECTOMY (2015) (0)
[Chemoprevention of prostatic carcinoma]. (2000) (0)
264 PERCENTAGE OF POSITIVE BIOPSY CORES IS AN ACCURATE PREDICTOR OF LYMPH NODE INVASION IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION (2007) (0)
743: Methylation of the E-Cadherin and the TIMP-3 Genes are Positive Prognostic Markers for Patients with Non-Muscle Invasive Bladder Carcinoma (2004) (0)
Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer (2018) (0)
FACTORS PREDICTING DISEASE FREE SURVIVAL IN PATIENTS WITH NODE POSITIVE PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION IN THE PSA ERA: ROLE OF ADJUVANT RADIOTHERAPY (2008) (0)
Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients (2016) (0)
293 Secondary radiotherapy after radical prostatectomy does not compromise urinary continence (2013) (0)
955: Use of Continuously Coded PSA Increases the Predictive Accuracy of the 1997 and the 2001 Partin Tables (2005) (0)
ONCOLOGICAL AND FUNCTIONAL OUTCOMES AFTER RP FOR HIGH OR VERY HIGH‐RISK PROSTATE CANCER – EUROPEAN VALIDATION OF THE CURRENT NCCN GUIDELINE: PD51‐12 (2017) (0)
A NEW ERA: AUTOMATED EXTRACTION OF DETAILED PROSTATE CANCER INFORMATION FROM NARRATIVELY WRITTEN HEALTH RECORDS. PIONEER WORK FROM A EUROPEAN TERTIARY CARE CENTER: PD37‐06 (2017) (0)
1426 TPD52 AS “8Q AMPLIFICATION TARGET“ WITH STRONG PROGNOSTIC RELEVANCE IN PROSTATE CANCER (2010) (0)
Impact of blood loss during radical prostatectomy on the functional outcome (2018) (0)
EAU BCR risk classification as decision tool for salvage radiatiotherapy (2020) (0)
Invasive Bladder Carcinoma, Progress in Basic Research, Diagnosis, Surgical and Medical Therapy: Heinrich Warner Stiftung, 2nd Symposium, Hamburg, November 1987 (1988) (0)
PROSTATE VOLUME AT INITIAL BIOPSY IS THE MOST IMPORTANT PREDICTOR OF REPEAT BIOPSY OUTCOME. VALIDATION OF A NOVEL PREDICTIVE TOOL (2006) (0)
[Immunotherapy of renal cell carcinoma. With special emphasis on therapy of the elderly patient]. (2003) (0)
Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers (2020) (0)
1273: Erection, Potency, Continence, and Qol Following Nerve Sparing and Non Nerve Sparing Retropubic Prostatectomy. Outcome Analysis of 1221 Ppatients with Validated Questionnaires (IIEF5, QLQ-C30, ICS BPH) (2005) (0)
445 Time to catheter removal after radical prostatectomy has no adverse effect on intermediate-and long-term continence rates (2016) (0)
[Prostate-specific antigen (PSA)]. (1995) (0)
DEVELOPMENT OF AN ACCURATE NOMOGRAM PREDICTING THE PROBABILITY OF PROSTATE CANCER AT SATURATION BIOPSY IN PATIENTS WITH PREVIOUS NEGATIVE BIOPSIES (2009) (0)
Impact of additional radiation and/or androgen deprivation therapy on functional outcomes after radical prostatectomy (2017) (0)
QUANTITATIVE REVERSE-TRANSKRIPTASE (RT)-PCR FOR THE DETECTION OF PSAmRNA BEFORE AND AFTER RADICAL PROSTATECTOMY (1999) (0)
PROSTATE CANCER ANTIGEN 3 (PCA3) SHOWS SIGNIFICANT ASSOCIATION TO PROSTATE CANCER VOLUME BUT NO CORRELATION TO TOTAL PROSTATE VOLUME OR SERUM PROSTATE SPECIFIC ANTIGEN (2009) (0)
[Benign prostatic hyperplasia]. (1995) (0)
The impact of high initial PSA (≥50 ng/ml) at the time of radical prostatectomy for clinically localized prostate cancer on cancer specific survival (2019) (0)
667: The Positive Surgical Margin (SM) is no Independent Predictor for Biochemical Failure after Radical Prostatectomy (RRP) (2005) (0)
1361 RADICAL RETROPUBIC PROSTATECTOMY IS POSSIBLE WITH GOOD FUNCTIONAL RESULTS IN PATIENTS WITH PARKINSONS DISEASE OR STATUS POST STROKE. RESULTS FROM MORE THAN 13000 PATIENTS (2012) (0)
[Vesico-ureteral reflux in patients with terminal renal failure. II. Causes of reflux (author's transl)]. (1982) (0)
973 Perfect cancer control after radical prostatectomy for patients with pathologically confirmed insignificant prostate cancer (2012) (0)
[Localized prostate cancer]. (1991) (0)
534: The Predictive Accuracy of the Partin Tables in Men with PSA Values in Excess of 20 NG/ML May be Limited (2006) (0)
ASSESSMENT OF ONCOLOGICAL OUTCOMES AFTER RADICAL PROSTATECTOMY ACCORDING TO PREOPERATIVE AND POSTOPERATIVE CAPRA RISK SCORES: RESULTS OF A LARGE, TWO‐CENTER EXPERIENCE.: MP47‐14 (2017) (0)
799 FULL FUNCTIONAL LENGTH URETHRAL SPHINCTER PRESERVATION DURING OPEN RADICAL PROSTATECTOMY (2010) (0)
Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2 : an Outcome Study ( renal cancer / lung metastasis / aerosol / interleukin-2 / inhalation / local therapy ) (2004) (0)
300 DETECTION OF CIRCULATING TUMOUR CELLS WITH THE CELLSEARCH SYSTEM® IN PERIPHERAL BLOD FROM PATIENTS WITH ADVANCED BLADDER CANCER (2009) (0)
Ureteroscopic therapy of “steinstrasse” after extracorporeal shock wave lithotripsy (ESWL) (1999) (0)
Oncologic long-term outcome in patients with pathologic Gleason 3+3 score at radical prostatectomy (2017) (0)
[Vesico-ureteral reflux in patients with terminal renal failure: I. Incidence and importance of reflux (author's transl)]. (1982) (0)
Reduction of early tumour recurrences in superficial bladder carcinoma using an extended resection protocol (2002) (0)
Pathological characteristics of primary high-grade adeno-carcinomas of the prostate treated by radical prostatectomy (2004) (0)
ABSTRACTS (pp 58–112) (2003) (0)
MP49-13 A TERTIARY GLEASON PATTERN EXERTS A DIFFERENT PROGNOSTIC EFFECT AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH DIFFERENT GLEASON SCORES (2014) (0)
Title · Committee · Table of Contents (2003) (0)
POD-08.05: The PCA3 assay is useful in guiding prostate biopsy (PB) decision in men with a prior negative biopsy (2007) (0)
MP60-13 PERIOPERATIVE MANAGEMENT OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY; RESULTS OF A PROSPECTIVE ASSESSMENT (2019) (0)
526 OUTCOME OF MULTIMODALITY TREATMENT OF HIGH-RISK LOCALIZED PROSTATE CANCER (CT3-4 OR PSA ≥20 NG/ML OR BIOPSY GLEASON SCORE ≥8) WITH RADICAL PROSTATECTOMY AS INITIAL STEP: A MULTI-INSTITUTIONAL OUTCOME STUDY OF 1413 PATIENTS (2009) (0)
572 Frozen section navigated radical prostatectomy significantly increase the frequency of nerve-sparing without compromising oncological outcome (2012) (0)
CEACAM1 is a mediator for invasion of the lamina propria in urothelial carcinoma (2002) (0)
ASSESSMENT OF PATHOLOGICAL PROSTATE CANCER CHARACTERISTICS IN MEN WITH FAVORABLE BIOPSY FEATURES (2008) (0)
8th Heinrich-Warner-Foundation-Symposium (2004) (0)
[Indication for therapy in urinary calculi]. (1997) (0)
1011 COMPARISON OF STAGE MIGRATION PATTERNS BETWEEN NORTH AMERICA AND EUROPE: AN ANALYSIS OF 11350 MEN (2007) (0)
Comparison of early salvage and adjuvant radiotherapy for non-organ-confined prostate cancer after radical prostatectomy (2020) (0)
2320 INITIAL AND REPEAT PROSTATE BIOPSY: COMPARATIVE PERFORMANCE ANALYSIS OF PSA, %FPSA, PROSTATE VOLUME AND URINARY PCA3 INCLUDING DEVELOPMENT OF NOVEL PCA3 CUT-OFF THRESHOLDS (2011) (0)
Obesity was associated with improved metastases-free survival after surgery in 13,667 prostate cancer patients (2017) (0)
353 A new era of data extraction: Example of automated extraction PSA values from electronic health records (2016) (0)
375 FROZEN SECTION NAVIGATED RADICAL PROSTATECTOMY SIGNIFICANTLY INCREASE THE FREQUENCY OF NERVE-SPARING WITHOUT COMPROMISING ONCOLOGICAL OUTCOME (2012) (0)
628 Nerve-sparing surgery technique but not the preservation of the neurovascular bundles leads to improved long-term continence rates after radical prostatectomy (2015) (0)
907 Lymph node–positive prostate cancer at radical prostatectomy: What is the optimal treatment? (2015) (0)
1350 PRESENCE OF DISSEMINATED TUMOR CELLS AT TIME OF RADICAL PROSTATECTOMY IS NOT ASSOCIATED WITH MORE ADVANCED OR POORLY DIFFERENTIATED DISEASE IN PATIENTS WITH LOCALIZED PROSTATE CANCER; POTENTIAL SOURCES OF RELAPSE? (2013) (0)
MP78-20 OPEN RADICAL PROSTATECTOMY IN TRANSPLANT PATIENTS. (2015) (0)
Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death (2023) (0)
DEVELOPMENT AND EXTERNAL VALIDATION OF AN EUROPEAN POST-OPERATIVE NOMOGRAM PREDICTING BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2008) (0)
1621: Microvessel Density is Signifiantly Associated with Pathologic Stage, Gleason Score and Biochemical Recurrence in Patients with Clinically Localized Prostate Cancer Undergoing Radical Retropubic Prostatectomy (2007) (0)
MP66-12 NEOADJUVANT ANDROGEN DEPRIVATION THERAPY PRIOR TO RADICAL PROSTATECTOMY FOR LOCALLY VERY ADVANCED (CT4) PROSTATE CANCER (2019) (0)
1949: A Comparison between the Prevalence of Prostate Cancer on Needle Biopsy between Referral and PCPT Placebo ARM in Men with PSA Values 0-4 NG/ML (2007) (0)
670 CLINICAL STAGE AND THE BIOPSY GLEASON-SCORE SIGNIFICANTLY AFFECT THE RATE OF FAVORABLE HISTOPATHOLOGICAL STAGE AT RADICAL PROSTATECTOMY IN PATIENTS WITH VERY HIGH PREOPERATIVE PSA -VALUES (≥20 NG/ML) (2011) (0)
360 Radical prostatectomy in immunosuppressed transplant patients: Surgical morbidity, disease characteristics, and prognostic aspects of 18 patients (2012) (0)
[Organization and financing of a center for kidney transplantation]. (1982) (0)
1494: Prostate Volume and High Grade Prostate Cancer: Are PCPT Findings Right? (2006) (0)
MP11-16 POSTOPERATIVE COMPLICATIONS OF CONTEMPORARY OPEN AND ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY USING STANDARDIZED REPORTING SYSTEMS (2018) (0)
MP69-03 ASSOCIATION BETWEEN LYMPH NODE COUNTS AND ONCOLOGICAL OUTCOMES IN LYMPH NODE POSITIVE PROSTATE CANCER PATIENTS (2016) (0)
What is learning curve of robot-assisted radical prostatectomy (RARP) in a very highvolume open radical prostatectomy (RRP) center: Experience of a propensity matched-pair analysis of 10719 patients (2018) (0)
Contemporary complications after radical prostatectomy (2017) (0)
SELECTIVE DISSECTION OF THE APEX DURING RADICAL PROSTATECTOMY ALLOWS BETTER TUMOUR CONTROL AND CONTINENCE (2006) (0)
681 Remarkably little influence of depression, worry and anxiety on preoperative function in patients scheduled for radical retropubic prostatectomy (2012) (0)
Bladder carcinogenesis and ecogenetics: A study on the role of N-acetyltransferase polymorphism and various risk factors in bladder cancer (1986) (0)
[Type and extent of preoperative imaging before radical prostatectomy]. (2010) (0)
PD29-08 IMPACT OF BLOOD LOSS DURING RADICAL PROSTATECTOMY ON FUNCTIONAL OUTCOMES (2018) (0)
REFINEMENTS OF NERVE SPARING RADICAL RETROPUBIC PROSTATECTOMY (2009) (0)
4 Transplanting cadaveric kidneys from old donors into old recipients — Good results with a lot of complications (2004) (0)
1000: Prediction and Natural History of Organ Confined Prostate Cancer after RP (2005) (0)
Impact of primary Gleason pattern on results of early salvage radiotherapy after radical prostatectomy (2019) (0)
[Perioperative incidence of transfusions after allogenic kidney transplantation]. (1999) (0)
MP58-09 INCIDENCE OF INSIGNIFICANT PROSTATE CANCER: A REPORT OF 955 CONSECUTIVE PATIENTS UNDERGOING RADICAL PROSTATECTOMY IN A HIGH VOLUME PROSTATE CANCER CENTER (2014) (0)
Oncological and functional outcomes after RP for high or very high-risk prostate cancer – European validation of the current NCCN guideline (2017) (0)
1024 CLINICAL T3 PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY: PATHOLOGICAL AND LONG-TERM OUTCOMES (2007) (0)
PD30-06 MORTALITY RISK FACTORS IN EUROPEAN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY. COMPETING RISK ANALYSIS WITH 15-YEARS FOLLOW UP (2015) (0)
Clinical and Pathohistological Prognosticators (2003) (0)
Standardizing patient-centered outcomes measurement in prostate cancer: An international, cross-disciplinary effort. (2014) (0)
256 INVERSE STAGE MIGRATION OF ORGAN CONFINED PROSTATE CANCER IN THE 21ST CENTURY IN EUROPE. A RETROSPECTIVE ANALYSIS OF 8346 RADICAL PROSTATECTOMY PATIENTS (2010) (0)
1390: Number of Positive Cores does not Improve Ability in Predicting Pathological Stage and Biochemical Recurrence (BCR) (2006) (0)
1713: Accuracy of Percent Free Psato Predict Prostate Cancer at Biopsy in PSA Ranges Lower than 2.5ng/ml (2007) (0)
Experimental Studies About Natural History and Reversibility of Hydronephrotic Atrophy Caused by Stable Partial Ureteral Obstruction (1987) (0)
633 Mortality risk factors in European prostate cancer patients treated with radical prostatectomy. Competing risk analysis with 15-years follow up (2015) (0)
THE 2002 AJCC PATHOLOGICAL T2 SUBSTAGES CONFER NO PROGNOSTIC INFORMATION ON THE RATE OF BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS WITH PATHOLOGICALLY ORGAN CONFINED DISEASE AT RADICAL PROSTATECTOMY (2006) (0)
The Martini-Clinic technique of open radical retropubic prostatectomy (2013) (0)
Editorial (2001) (0)
A gene expression signature suggests molecular alterations preceding prostate tumor manifestation (2008) (0)
Early urinary continence a reliable marker for further functional outcomes (2020) (0)
Imaging , Diagnosis , Prognosis Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model : Identi fi cation of b ( 1 , 6 )-Branched Oligosaccharides as a Marker of Tumor Progression (2012) (0)
The effect of surgical volume on the rate of secondary therapy after radical prostatectomy (2007) (0)
MP53-12 EAU BCR RISK CLASSIFICATION AS DECISION TOOL FOR SALVAGE RADIOTHERAPY (2020) (0)
866: Value of T-PSA and %F-PSA as a Preoperative Predictive Marker for Pathological Stage and Biochemical Recurrence in Low PSA Prostate Carcinomas (2006) (0)
[Etiology of urinary tract infections]. (1984) (0)
609 TMPRSS2-ERG GENE FUSION IS STRONGLY ASSOCIATED WITH ELEVATED ANDROGEN RECEPTOR EXPRESSION IN EARLY PROSTATE CANCER (2011) (0)
Development of tumor selection on the basis of pathological staging in clinically localized prostate carcinoma (1998) (0)
615 A COMPARISON BETWEEN THE PREVALENCE OF PROSTATE CANCER ON NEEDLE BIOPSY BETWEEN REFERRAL AND PCPT PLACEBO ARM IN MEN WITH PSA VALUES 0-4 NG/ML (2007) (0)
Development and validation of a nomogram for prediction of positive systematic sextant biopsy (2002) (0)
639 TIME TRENDS OF BIOCHEMICAL RECURRENCE (BCR) FOLLOWING RADICAL PROSTATECTOMY AMONG 1590 BCR PATIENTS. PROGNOSTIC VALUE FOR CLINICAL PROGRESSION (2011) (0)
1413: Detection and Comparison of free Cellular DNA Levels in Plasma of BPH and Prostate Cancer Patients (2005) (0)
[Sonography for monitoring kidney transplants]. (1982) (0)
144: Surgical Margin Status in European Versus North American Patients at Radical Prostatectomy (2006) (0)
Reply of Dr. Huland and Dr. Busch (1983) (0)
[Kidney transplantation in urology. Past--present--future]. (2006) (0)
845: Extended Biopsy Schemes are Associated with Similar Pathological Characteristics but Lower Biochemical Recurrence than Sextant Biopsy (2007) (0)
PD43-07 IMPACT OF POSITIVE SURGICAL MARGIN LENGTH AND GLEASON GRADE AT THE MARGIN ON ONCOLOGIC OUTCOMES IN PATIENTS WITH NON-ORGAN-CONFINED PROSTATE CANCER (2020) (0)
Abstract 567: Multiparametric analysis of an ultra-large prostate cancer tissue microarray with attached histo-pathological, clinical, and molecular data: A tool for rapid evaluation of clinically relevant gene sets (2014) (0)
Risk of metastasis in patients with delayed biochemical recurrence 10 years after radical prostatectomy (2020) (0)
V11-11 THE MICHL TECHNIQUE TO REDUCE THE INCIDENCE OF SYMPTOMATIC LYMPHOCELES FOLLOWING ROBOT ASSISTED RADICAL PROSTATECTOMY.PATHOPHYSIOLOGY, SURGICAL PROCEDURE, AND EARLY RESULTS OF A RANDOMISED TRIAL (2019) (0)
1071 Diabetes and therapy of diabetes had no impact on BCR following radical prostatectomy (RP): Results from nearly 4200 contemporary patients (2014) (0)
414 DIFFERENCES IN CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF PATIENTS DIAGNOSED WITH CLINICALLY LOCALIZED PROSTATE CANCER, SUBJECTED TO EITHER OPEN OR ROBOTIC-ASSISTED RADICAL PROSTATECTOMY (2007) (0)
Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with non-organ-confined prostate cancer (2020) (0)
MP72-17 IMPACT OF PRIMARY GLEASON PATTERN ON RESULTS OF EARLY SALVAGE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY (2019) (0)
Conversion from Classical Immunosuppressive Therapy to Cyclosporin A in Renal Allograft Rejection and Treatment of Acute Rejection in Patients on Cyclosporin A (1985) (0)
PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer (2018) (0)
CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo (2021) (0)
Is serial iodohippurate renography at the bedside reliable enough to monitor renal transplants? (1983) (0)
802 Presence of disseminated tumor cells at time of radical prostatectomy is not associated with more advanced or poorly differentiated disease in patients with localized prostate cancer; potential sources of relapse? (2013) (0)
DEFINING THE IDEAL NUMBER OF NODES TO REMOVE AT PELVIC LYMPHADENECTOMY FOR PROSTATE CANCER: VALIDATION OF A NOMOGRAM FOR INTERMEDIATE - TO HIGH RISK PATIENTS (2006) (0)
[Pyelonephritic scar formation]. (1993) (0)
[Renal cell carcinoma--any new developments?]. (1999) (0)
LONG TERM OUTCOME OF PATIENTS WITH POSITIVE LYMPH NODES DURING RADICAL PROSTATECTOMY: SURVIVAL BENEFIT OF PATIENTS WITH COMPLETED VS. ABANDONED SURGERY (2008) (0)
Gleason grade grouping: The significance of primary Gleason 5 in patients with Gleason grade group 5 (2019) (0)
729: A Risk Adjusted Follow Up Scheme after Radical Prostatectomy for Prostate Cancer (2007) (0)
[Prostate cancer]. (2000) (0)
Inhalation of Natural Interleukin-2: Effectivity and Toxicity in Patients with Pulmonary Metastases of Renal Cell Carcinoma (1994) (0)
Role of angiopoietins (ANG1 and ANG2) and their receptor TIE-2 in the vascularisation of human prostate cancer (2002) (0)
PD29-11 IMPACT OF BILATERAL NEUROVASCULAR BUNDLE PRESERVATION ON ONCOLOGICAL OUTCOMES IN NON-ORGAN CONFINED PROSTATE CANCER (2018) (0)
397 What impact on prognosis has time from diagnosis to treatment in patients with localized prostate cancer (2004) (0)
1029 Evaluation of free psa sub forms and human glandular kallikrein 2 levels as predictors of biochemical recurrence after radical prostatectomy for localized prostate cancer (2005) (0)
128 POSITIVE SURGICAL MARGINS INCREASE THE RISK OF BIOCHEMICAL RECURRENCE INDEPENDENTLY FROM PATHOLOGICAL STAGE OR GRADE (2007) (0)
[Prostatic carcinoma]. (1996) (0)
1941 FULL FUNCTIONAL LENGTH URETHRAL SPHINCTER PRESERVATION DURING OPEN RADICAL PROSTATECTOMY (2010) (0)
VARIATION OF BIOPSY PROSTATE CANCER DETECTION RATE AMONG INDIVIDUAL INVESTIGATORS (2006) (0)
Value of Digital Rectal Examination, Determination of Prostate-Specific Antigen Concentration and the Use of Transrectal Ultrasonography (1996) (0)
Podium SessionPodium Session 3: Prostate Cancer, AdvancedPOD-03.01 Risk Assessment for Prostate Cancer Metastases by Using the Capra Score: Results from 3239 European Patients (2011) (0)
619: Combination of Gene Expression and Genetic Alterations in Bladder Carcinoma for Improvment of Molecular Diagnosis (2006) (0)
COMPETITIVE EVALUATION OF THE 1992 AND 2002 PATHOLOGICAL T3 SUBSTAGES IN PREDICTION OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2006) (0)
Inhalational Interleukin-2 in the Treatment of Pulmonary Metastases in Patients with Renal Cell Carcinoma (1995) (0)
Screening for p53 Mutations in Superficial Transitional Cell Carcinoma of the Bladder with an Improved Technique Consisting of Microdissection, Polymerase Chain Reaction, Temperature Gradient Gel Electrophoresis, and Direct Sequencing (1999) (0)
ABSTRACTS (pp 113–172) (2003) (0)
202 Determination of urinary protein pattern in bladder carcinoma by proteomic analyses (2004) (0)
ABSTRACTS (pp 1–57) (2003) (0)
254: HA and HAASE: Diagnostic Markers with Function in Bladder Tumor Growth and Muscle Invasion (2004) (0)
1147: Favorable Long-Term Outcomes in Patients with Seminal Vesicle Invasion or Lymph Node Invasion at Radical Prostatectomy (2007) (0)
MP83-07 SALVAGE RADICAL PROSTATECTOMY FOR RECURRENT PROSTATE CANCER: VERIFICATION OF EAU GUIDELINE CRITERIA (2015) (0)
252 COMPARATIVE ASSESSMENT OF CLINICAL PROGRESSION-FREE SURVIVAL RATES OF PATIENTS WITH POSITIVE LYMPH NODES DURING RADICAL PROSTATECTOMY: COMPLETED VS. ABANDONED RADICAL PROSTATECTOMY (PTX). (2007) (0)
INCORPORATION OF HUMAN GLANDULAR KALLIKREIN 2 INTO A STANDARD NOMOGRAM TO PREDICT BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY. SIGNIFICANT ADVANTAGE FOR MEN WITH A PRE-TREATMENT PSA ≤ 10ng/ml (2008) (0)
Treatment of pulmonary metastases from kidney cell carcinoma with inhalational interleukin-2. 10-year experience Hamburger Unicenter (1999) (0)
801: What Pathologic Feature Impacts Outcome in Men Without High-Grade Cancer Treated by Radical Prostatectomy? (2004) (0)
Treatment of Acute Cellular Rejection in Renal Transplant Patients on Cyclosporin a with Complete T-Cell-Elimination by Antithymocyte Globulin (1987) (0)
1131 RADICAL PROSTATECTOMY IN ELDERLY PATIENTS, TEMPORAL TRENDS AND FUNCTIONAL RESULTS OF URINARY CONTINENCE ONE YEAR POSTOPERATIVE (2012) (0)
402Influence of the body mass index (BMI) on postoperative continence and potency after radical prostatectomy (2005) (0)
MP78-18 IMPACT OF CAPSULAR INCISION DURING RADICAL PROSTATECTOMY ON BIOCHEMICAL RECURRENCE RATES (2015) (0)
1650: Significant Upgrading Affects One in Four Men Diagnosed with Prostate Cancer. Predictive Nomogram (2006) (0)
256: Plasma Tissue Factor (TF) Antigen, Cellular Microparticles, and Markers of Coagulation and Platelet Activation in Localized Prostate Cancer (2006) (0)
1714: Percentage of Free PSA is the Most Informative Predictor of the Risk of Prostate Cancer on Initial Biopsy Across all Ages (2007) (0)
631A comparative study of cytology and biomarkers: HA-HAASE, hemastix detection, BTA-STAT and UBC-rapid for bladder cancer detection in urine (2005) (0)
520 PELVIC LYMPH NODE DISSECTION SHOULD BE OMITTED IN LOW RISK PROSTATE CANCER PATIENTS. RESULTS OF A MATCHED ANALYSIS (2009) (0)
[Influence of transrectal endosonography on the clinical staging of impalpable prostate cancer. A controversy over the TNM system]. (2004) (0)
1953: Transplanting Cadaveric Kidneys from Old Donors into Old Recipients - Good Renal Function with Significant Morbidity (2004) (0)
691 DIGITAL RECTAL EXAMINATION IS AN INDEPENDENT PREDICTOR OF PROSTATE CANCER AT INITIAL BIOPSY IN CONTEMPORARY MEN EXPOSED TO EXTENDED CORE BIOPSY (2007) (0)
595 EARLY COMPLICATION RATE OF OPEN RETROPUBIC PROSTATECTOMY ACCORDING TO THE CLAVIEN CLASSIFICATION SYSTEM: INFLUENCE OF NERVE SPARING AND LYMPHADENECTOMY (2010) (0)
Transforming growth factor-β1 (TGF-β1) levels in plasma of patients with prostate cancer and benign prostatic hyperplasia (BPH) (1998) (0)
808 The impact of not determinable surgical margins after radical prostatectomy (2015) (0)
730Prostate cancer (PCA) patients display significant higher plasma levels of cell- free DNA (2005) (0)
[Prostate carcinoma: many developments in diagnosis and treatment]. (2003) (0)
Vol. 26, Supplement 4, October 2003 / Title / Table of Contents (2003) (0)
465: Proposal for a Correction of the AJCC Staging System for Prostate Cancer Patients Treated with Radical Prostatectomy (2007) (0)
Impact of adjuvant radiotherapy in patients with high burden lymph node metastases after radical prostatectomy (2020) (0)
A CRITICAL APPRAISAL OF THE ABILITY OF BODY MASS INDEX (BMI) TO PREDICT HIGH-GRADE PROSTATE CANCER (PCA) (2006) (0)
445 Does neo-adjuvant hormontherapy adversely affect postoperative potency rates after nerve sparing radical prostatectomy? (2004) (0)
Erection, potency, and sexual intercourse following N. suralis transplantation compared to nerve sparing prostatectomy. A questionnaire based analysis (2003) (0)
1404: Significance of Positive Surgical Margin on Biochemical Recurrence Rates in Organ Confined Prostate Cancer (2007) (0)
High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer (2018) (0)
911 Biopsy-specific PCA3-based prostate biopsy nomograms are highly accurate (2012) (0)
V37 A feasible and time-efficient adaption of the NeuroSAFE intraoperative frozen section technique to DaVinci-robot-assisted radical prostatectomy (2014) (0)
1335: 21% Five-Year Survival in High Risk Metastatic Renal Cell Carcinoma Patients on Inhaled Interleukin-2: A German Outcome Study (2005) (0)
956: Evaluation of Human Glandular Kallikrein 2 and Free Prostate-Specific Antigen Levels as Predictors of Biochemical Recurrence after Radical Prostatectomy for Localized Prostate Cancer (2005) (0)
Renal transplantation using cyclosporine with and without regard to HLA matching: a randomized prospective unicenter study. (1989) (0)
Study „Prostate Cancer Outcomes - Compare & Reduce Variation“. Status report 09/30/2016 (2016) (0)
The effect of tissue ischemia on gene expression in prostate tissue (2006) (0)
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer (2019) (0)
Local intratumoral immunotherapy of prostate cancer with interleukln-2 reduces tumor growth significantly (1997) (0)
Intravesical Cytostatic Instillations for Prophylaxis of Recurrent Tumors in Patients with Superficial Bladder Carcinoma: Result of a Prospective Multicentric Study (1987) (0)
961 CIRCULATING TUMOUR CELLS IN NON-METASTATIC BLADDER CANCER ARE ASSOCIATED WITH WORSE OUTCOME (2010) (0)
The Significance of Immune Cytological Diagnostics for Bladder Carcinoma (1991) (0)
1879: Larger Prostate Glands are Associated with a Lower Rate of Upgrading between Biopsy and Radical Prostatectomy (2007) (0)
[100 years prostate cancer: yesterday--today--tomorrow]. (2006) (0)
O11 High LIG4 expression is tightly linked to presence of TMPRSS2-ERG rearrangement, PTEN deletions and early biochemical recurrence in operated prostate cancer (2013) (0)
282 HOLMIUM LASER ENUCLEATION THE PROSTATE AND INCIDENTAL PROSTATE CANCER: SIGNIFICANCE OF HISTOLOGY IN LASERPROSTATECTOMY (2009) (0)
300Frozen section for the management of intraoperatively detected palpable tumour lesions during nerve-sparing scheduled radical prostatectomy (2005) (0)
Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study (2018) (0)
A modified Pak test to diagnose hypercalciuria in outpatients. (1985) (0)
New markers for testicular non-seminoma and seminoma: HA and HAS-1 (2003) (0)
OBESITY WAS ASSOCIATED WITH IMPROVED METASTASES‐FREE SURVIVAL AFTER SURGERY IN 13,667 PROSTATE CANCER PATIENTS: MP47‐04 (2017) (0)
Quantification of total and high-grade cancer in biopsy cores improves the prediction of PSA recurrence after Radical Prostatectomy (RP) (2002) (0)
658 THE EXTENT OF DISSECTED PELVIC LYMPH NODES AT RADICAL PROSTATECTOMY HAS NO EFFECT ON PROSTATE CANCER OUTCOME (2010) (0)
189: Surgical Volume is Related to the Rate of Positive Surgical Margins at Radical Prostatectomy in European Patients (2005) (0)
Clinical significance of EGFR and HER2 overexpression in prostate cancer (2006) (0)
PROSTATE CANCER DETECTION AND OUTCOME AFTER INITIAL, CONSECUTIVE AND REPEAT SATURATION BIOPSY (2008) (0)
1646: PSA Represents a Highly Accurate Predictor of Pathologic Stage and Surgical Outcomes (2006) (0)
MP68-19 DEVELOPMENT AND CHARACTERISATION OF A SPONTANEOUSLY METASTATIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL OF HUMAN PROSTATE CANCER (PCA) (2019) (0)
MP60-10 IMPACT OF POSITIVE SURGICAL MARGIN LENGTH AND GLEASON GRADE AT THE MARGIN ON BIOCHEMICAL RECURRENCE IN PATIENTS WITH ORGAN-CONFINED PROSTATE CANCER (2019) (0)
PD-0671: Matched pair analysis of salvage radiotherapy vs observation for post-prostatectomy PSA recurrence (2020) (0)
904 DIAGNOSIS AND TREATMENT OF PROSTATE CANCER WITH RADICAL PROSTATECTOMY AT AN EARLIER AGE DOES NOT AFFECT THE PATHOLOGICAL STAGE (2007) (0)
Abstract 3741: Improving Gleason scoring in prostate cancer: Development and clinical value of the Molecular Integrative Quantitative Gleason (MIQ-Gleason) (2017) (0)
636 INSURANCE STATUS IS A DETERMINANT OF THE STAGE AT PRESENTATION AND OF CANCER CONTROL IN EUROPEAN MEN SUBJECTED TO RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER (2007) (0)
[The diagnosis of female stress incontinence--the value of the clinical examination, anamnesis and urodynamics]. (1992) (0)
[Kidney cysts in the computerized tomogram--incidence and therapeutic consequences]. (1983) (0)
Survival analysis in patients with pulmonary metastatic renal cell carcinoma (MRCC) treated by inhaled interleukin-2 (IL-2) compared to prognostic stratification models (2003) (0)
1640 USE OF PROERECTILE MEDICATION IS A SIGNIFICANT INDEPENDENT RISK FACTOR FOR PSA RECURRENCE IN PATIENTS AFTER RADICAL PROSTATECTOMY (2012) (0)
1143: Positive Surgical Margins Increase the Risk of Biochemical Recurrence Independently from Pathological Stage or Grade (2007) (0)
2318 CRITICAL ASSESSMENT OF PRE-OPERATIVE URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF LOCALLY ADVANCED AND AGGRESSIVE PROSTATE CANCER (2011) (0)
PROSTATECTOMY ON BIOCHEMICAL RECURRENCE RATES (2015) (0)
617Prostate cancer (PCA) patients display specific genetic alterations in free circulating DNA (2005) (0)
83 Transition zone cancers of the prostate display complex chromosomal imbalances detected by CGH (2005) (0)
CYSTOGRAM AFTER RADICAL PROSTATECTOMY IS RELIABLE WHEN PERFORMED BY TRANSRECTAL ULTRASOUND (2006) (0)
MP83-18 LYMPHATIC VESSEL INVASION PREDICTS BIOCHEMICAL RECURRENCE IN ORGAN CONFINED PROSTATE CANCER. RESULTS OF 2316 EUROPEAN PATIENTS WITHOUT LYMPHNODE DISSECTION (2015) (0)
Immunocytology as a possible marker to identify patients who require prophylaxis. (1990) (0)
1014 Salvage radical prostatectomy for recurrent prostate cancer: Validation of EAU guideline criteria (2015) (0)
General & Epidemiological Trends & Socioeconomics: Evidence-based Medicine & Outcomes IIMP9-04 A NOVEL COMPREHENSIVE COMPLICATION INDEX BY CLAVIEN IN PATIENTS WITH RADICAL PROSTATECTOMY. (2015) (0)
MP-13.01 Radical Prostatectomy in Men with Continued Oral Aspirin Medication: Revisiting an Old Paradigm? (2011) (0)
[Results and specific problems in unrestricted indications for kidney transplantation in children]. (1984) (0)
799: Epidermal Growth Factor Receptor (EGFR) is a Potential Therapeutic Target in Prostate Cancer (2006) (0)
1964: Digital Rectal Examination is an Independent Predictor of Prostate Cancer at Initial Biopsy in Contemporary Men Exposed to Extended Core Biopsy (2007) (0)
680 ELDERLY PATIENTS ARE AT A MORE ELEVATED RISK OF PT 3 PROSTATE CANCER: RESULTS OF A EUROPEAN SINGLE CENTER (2010) (0)
1210 BIOPSY-SPECIFIC PCA3- BASED PROSTATE BIOPSY NOMOGRAMS ARE HIGHLY ACCURATE (2012) (0)
Late abstracts 186–187 (2005) (0)
592 LONG TERM PROPHYLAXIS WITH MITOMYCIN C (MMC) SIGNIFICANTLY REDUCES TUMOR RECURRENCE COMPARED TO SHORT TERM PROPHYLAXIS WITH MMC OR BACILLUS CALMETTE-GUERIN (BCG) IN NON MUSCLE-INVASIVE BLADDER CANCER (NMIBC) (2007) (0)
[Quantitative immunocytology as a marker for indications and follow-up of recurrence prevention of superficial urinary bladder cancers]. (1989) (0)
2217 HIGH DETECTION RATES OF SIGNIFICANT PROSTATE CANCER OCCUR WITH REPEAT BIOPSIES (2012) (0)
Complicated renal cysts - is operation always necessary? (2002) (0)
[Polychemotherapy in advanced bladder cancer. Practicality and clinical results]. (1992) (0)
Use of aerosols containing cytokines and aerosols containing cytokines themselves. (1990) (0)
Extra Corporal Shock Wave Lithotripsy (ESWL) compared to ureteroscopic (URS) stone removal in small distal ureteral stones less than 6MM in size (2002) (0)
914 LARGER PROSTATE GLANDS ARE ASSOCIATED WITH A LOWER RATE OF UPGRADING BETWEEN BIOPSY AND RADICAL PROSTATECTOMY (2007) (0)
388: Clinical T3 Prostate Cancer Treated with Radical Prostatectomy: Pathological and long-term Outcomes (2007) (0)
PREDICTION OF INSIGNIFICANT CANCERS: HOW GOOD ARE CURRENT NOMOGRAMS? (2006) (0)
Development and characterisation of a spontaneously metastatic patient-derived xenograft (PDX) model of human prostate cancer (PCa) (2019) (0)
801 ACCURACY OF PERCENT FREE PSA IN PSA RANGES LOWER THAN 2.5NG/ML (2007) (0)
1646 DISEASE CHARACTERISTICS OF MEN YOUNGER THAN 50 YEARS TREATED WITH RADIACAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER IN COMPARISON TO OLDER MEN IN EUROPE (2011) (0)
PD40-06 A COMPARATIVE STUDY OF ROBOT-ASSISTED LAPAROSCOPIC AND OPEN RETROPUBIC RADICAL PROSTATECTOMY IN 10,790 MEN TREATED BY HIGHLY TRAINED SURGEONS FOR BOTH PROCEDURES – THE MARTINI-KLINIK EXPERIENCE (2019) (0)
1014 OLDER PATIENTS SUFFER FROM DELAYED RADICAL CYSTECTOMY (2010) (0)
1080 INFLUENCE OF HIGH DOSE LOW MOLECULAR WEIGHT HEPARIN (LMWH) ON BLOOD TRANSFUSION AND LYMPHOCELE RATE IN OPEN RADICAL PROSTATECTOMY (2011) (0)
Early detection of localized prostate cancer (1997) (0)
928 CIRCULATING TUMOUR CELLS IN NON-METASTATIC BLADDER CANCER ARE ASSOCIATED WITH WORSE OUTCOME (2010) (0)
641 CRITICAL ASSESSMENT OF URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF AGGRESSIVE PROSTATE CANCER (GLEASON score ≥ 7) AT BIOPSY (2011) (0)
Diagnosis of renal transplant rejection (1988) (0)
μRNA expression arrays reveal an association of multiple μRNAs to prostate cancer (2007) (0)
1474: Prevalence of Prostate Cancer in Patients with Prostate Specific Antigen < 4 NG/ML and a Normal Digital Rectal Examination in a European Referral Population (2006) (0)
1018 Difficult radical prostatectomy did not cause inferior functional outcome (2013) (0)
1425 THE HUMAN EXOGENOUS GAMMARETROVIRUS XMRV: PREVALENCE IN PROSTATE CANCER TISSUE AND VIRAL MECHANISMS CONTRIBUTING TO TUMORIGENESIS (2010) (0)
1578: BMI and its Ability to Improve Prediction of Biochemical Recurrence (BCR) after Radical Prostatectomy (RP): Does a Statistically Significant Marker Always Improve Predictive Accuracy in Multivariate Models? (2006) (0)
LBA4 The International Consortium for Health Outcome Measurements (ICHOM) activities on prostate cancer (2014) (0)
1027 The predictive accuracy of the 1997 and 2001 partin tables may be enhanced with the use of percent free PSA (2005) (0)
29 Does the body mass index independently impact prognosis of prostate cancer (2005) (0)
128 Serum concentrations of human glandular kallikrein 2 (HK2) but not free PSA, total PSA or %FPSA permit discrimination of pathologically organ-confined (OC) from non-organ confined (NOC), non-palpable (clinical stage T1C) prostate cancer (2004) (0)
380 FUNCTIONAL AND ONCOLOGICAL OUTCOME OF PATIENTS YOUNGER THAN 50 YEARS TREATED WITH RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER IN A NON SCREENED EUROPEAN POPULATION (2012) (0)
1028 Tumour volume and percentage of high-grade tumour volume represent important predictors of positive surgical margins (+sm) and of the time to biochemical relapse (BCR) after radical prostatectomy (RP) (2005) (0)
Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer (2020) (0)
MP-16.12 Pre-Operative Urinary Prostate CAncer Gene 3 (PCA3) in the Prediction of Small Tumor Volume, Insignificant, Locally Advanced and Aggressive Prostate Cancer (2011) (0)
Treatment of localized prostate cancer. (2007) (0)
MP80-11 TUMOR CHARACTERISTICS, ONCOLOGICAL AND OVERALL OUTCOME AFTER RADICAL PROSTATECTOMY IN MEN 75 YEARS AND OLDER (2016) (0)
1341 THE MAJORITY OF MEN UNDERGOING RADICAL PROSTATECTOMY AFTER REPEAT BIOPSY HARBOR SIGNIFICANT PROSTATE CANCER (2012) (0)
120 CLINICIANS CAN ACCURATELY SELECT PATIENTS IN WHOM LYMPHADENECTOMY MAY BE SAFELY OMITTED AT RADICAL PROSTATECTOMY (2007) (0)
330: Prospective Validation of a Nomogram Predicting side Specific Extra Capsular Extension of Prostate Cancer (2007) (0)
135 DURABLE CANCER CONTROL IN HIGH RISK PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY (2007) (0)
PD30-07 ADHERENCE TO EUROPEAN ASSOCIATION OF UROLOGY GUIDELINE RECOMMENDATION FOR PELVIC LYMPH NODE DISSECTION IN AN EUROPEAN HIGH-VOLUME CENTER (2015) (0)
804 Radical prostatectomy in transplant patients (2015) (0)
908 RADICAL RETROPUBIC PROSTATECTOMY AND TRANS- PLANTATION OF THE SURAL NERVE: 10 YEARS AFTER (2011) (0)
800: Defining the Ideal Number of Nodes to Remove at Pelvic Lymphadenectomy for Prostate Cancer: Validation of a Nomogram for Intermediate to High Risk Patients (2006) (0)
BMI AND ITS ABILITY TO IMPROVE PREDICTION OF BIOCHEMICAL RECURRENCE (BCR) AFTER RADICAL PROSTATECTOMY (RP): DOES A STATISTICALLY SIGNIFICANT MARKER ALWAYS IMPROVE PREDICTIVE ACCURACY IN MULTIVARIATE MODELS? (2006) (0)
681 NERVE SPARING RADICAL PROSTATECTOMY IN PROPERLY SELECTED PATIENTS WITH PT3 PROSTATE CANCER DOES NOT UNDERMINE THE RATES OF POSITIVE SURGICAL MARGINS (2010) (0)
Prospective, long-term analysis of quality-of-life during interleukin (IL)-2 immunotherapy (2002) (0)
260Development of a nomogram predicting the probability of PCA Gleason sum upgrading between biopsy and radical prostatectomy (RP) pathology (2005) (0)
132 MORE EVIDENCE THAT LOCAL TREATMENT MATTERS: AN UPDATED SURVIVAL ANALYSIS OF RADICAL PROSTATECTOMY AND PELVIC LYMPHADENECTOMY (PLND) (PT2-4) VERSUS PLND ALONE (PTX) IN MEN WITH LYMPH NODE POSITIVE DISEASE (2010) (0)
MP66-14 PSA PERSISTENCE AFTER RADICAL PROSTATECTOMY AND ITS IMPACT ON ONCOLOGIC OUTCOMES (2019) (0)
683: Frozen Section for the Management of Intraoperatively Detected Palpable Tumor Lesions During Nerve-Sparing Scheduled Radical Prostatectomy (2005) (0)
MP46-13 DIABETES AND THERAPY OF DIABETES HAD NO IMPACT ON BCR FOLLOWING RADICAL PROSTATECTOMY (RP). RESULTS FROM NEARLY 4200 CONTEMPORARY PATIENTS (2014) (0)
Latent Prostatic Carcinoma: Epidemiology - Biology - Clinical Significance - Detection and Prevention (2001) (0)
248 DEVELOPMENT AND INTERNAL VALIDATION OF A PRE-OPERATIVE NOMOGRAM PREDICTING THE PROPABILITY OF TRANSITION ZONE PROSTATE CANCER AT FINAL PATHOLOGY (2007) (0)
Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer (2020) (0)
Six years experience using inhalatory interleukin-2 in pulmonary metastatic renal cell carcinoma (1997) (0)
Molecular Evolution of Ear ly-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories Graphical (2018) (0)
A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy (2020) (0)
Perioperative blood transfusions after allogenic renal transplantation (2016) (0)
895 RISK ASSESSMENT FOR PROSTATE CANCER METASTASES BY USING THE CAPRA SCORE: RESULTS FROM 3209 EUROPEAN PATIENTS (2011) (0)
State-of-the-art automated extraction of detailed pathological data from narratively written electronic health records (2018) (0)
Prognostic Factors in Kidney Cancer and New TNM Classification (2008) (0)
727: Early Recurrences after Radical Prostatectomy for Prostate Cancer: Can we Identify Those Patients? (2007) (0)
MP64-05 A NEW MODEL FOR PREDICTION OF HIGH-RISK FEATURES AMONG UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER PATIENTS (2021) (0)
Evaluation of effective vinblastine-sulfate dosage in different renal cell carcinomas after transplantation to the NU/NU mice. (1982) (0)
Subject Index Vol. 22, 1999 (1999) (0)
1651 PALLIATIVE RADICAL CYSTECTOMY IN PATIENTS WITH METASTATIC BLADDER CANCER - WHAT IS IT WORTH? (2010) (0)
Free PSA fraction, nicked PSA, discriminates prostate cancer from non-cancerous condition (2003) (0)
855 ELDERLY PATIENTS ARE AT AN MORE ELEVATED RISK OF PT3 PROSTATE CANCER: RESULTS OF A MULTIVARIABLE ANALYSIS (2010) (0)
Therapy and Prophylaxis of Superficial Bladder Carcinomas (1986) (0)
Abstract 2989: Expression of immune checkpoints proteins and their prognostic relevance in prostate cancer (2017) (0)
PD37-10 LONG-TERM ONCOLOGICAL OUTCOMES IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2016) (0)
Introduction and New Aspects of the Biology of Prostate Carcinoma (1996) (0)
The Importance of Positive Section Margins in Patients With High Risk Prostate Cancer Treated With Radical Prostatectomy (2009) (0)
MP80-17 LONG-TERM ONCOLOGICAL OUTCOMES IN PATIENTS WITH PATHOLOGIC GLEASON 3+3 SCORE AT RADICAL PROSTATECTOMY (2016) (0)
1059 COMPARISON BETWEEN COMPLICATION RATES, LENGTH OF STAY AND COSTS OF MINIMALLY INVASIVE VS. OPEN RADICAL PROSTATECTOMY (2010) (0)
635 External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort (2015) (0)
1483 THE RATES OF PARTIAL NEPHRECTOMY IN PATIENTS WITH SMALL RENAL MASSES ARE INCREASING: A POPULATION-BASED STUDY (2010) (0)
MP53-02 SALVAGE RADIOTHERAPY VERSUS OBSERVATION FOR BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY FOR PROSTATE CANCER: A MATCHED PAIR ANALYSIS (2020) (0)
166 Differences in biomolecular characteristics between high grade and low grade prostate cancers (2004) (0)
868 THE RATE OF SIDE SPECIFIC ECE IS CLOSELY RELATED TO THE RATE OF IPSILATERAL LYMPH NODE INVASION IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY (2010) (0)
Effect of tumor characteristics on functional outcomes after radical prostatectomy (2020) (0)
1495: High Incidence of Prostate Cancer using a Saturation Biopsy Scheme after Several Negative Biopsy Series (2005) (0)
PD34-05 PREDICTION OF DISTANT METASTASES IN PATIENTS WITH LYMPH NODE INVASION AT TIME OF RADICAL PROSTATECTOMY (2014) (0)
745: Frequent Methylation of Apoptosis-Associated Genes in Bladder Cancer Cell Lines, Tumor Samples, and Urine Samples for Diagnosis of Bladder Cancer (2004) (0)
Use zytokinhaltiger aerosols and zytokinhaltige aerosols themselves. (1990) (0)
Influence of thromboxane A2 inhibition on the development of hydronephrotic atrophy. (1986) (0)
The use of aerosols, as well as cytokinholdige cytokholdige aerosols per se (1990) (0)
429 ASSOCIATION OF NUMEROUS MICRO-RNAS (μRNAS) WITH PROSTATE CANCER INITIATION AND PROGRESSION (2007) (0)
PD27-03 NERVE-SPARING RADICAL PROSTATECTOMY (NSRP) USING THE NEUROSAFE TECHNIQUE IS ONCOLOGICALLY SAFE: RESULTS AFTER 20 YEARS OF EXPERIENCE (2023) (0)
521 THE ROLE OF ADJUVANT TREATMENT STRATEGIES AFTER SURGERY FOR HIGH-RISK LOCALIZED PROSTATE CANCER (2009) (0)
PELVIC LYMPH NODE DISSECTION SHOULD BE OMITTED IN LOW RISK PROSTATE CANCER PATIENTS. RESULTS OF A MATCHED ANALYSIS (2009) (0)
Oncologic outcomes after radical prostatectomy for high risk prostate cancer: Impact of various definitions on cancer-specific and overall mortality (2019) (0)
119 NO DIFFERENCES IN BIOCHEMICAL RECURRENCE BETWEEN NO AND NX PATIENTS SUBJECTED TO RADICAL PROSTATECTOMY: A MATCHED ANALYSES ON 5977 PATIENTS (2007) (0)
North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients (2018) (0)
[Kidney transplantations in childhood]. (1982) (0)
[Kidney transplantation: the end of classical immunosuppression with azathioprine?]. (1984) (0)
[Biological markers in urology]. (1990) (0)
NERVE-SPARING RADICAL PROSTATECTOMY DOES NOT UNDERMINE THE RATE OF BIOCHEMICAL RECURRENCE IN CAREFULLY SELECTED PATIENTS WITH PATHOLOGICALLY CONFIRMED EXTRACAPSULAR EXTENSION (2008) (0)
MP51-18 ADJUVANT AND SALVAGE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY DOES NOT COMPROMISE URINARY CONTINENCE (2014) (0)
A PRE-TREATMENT NOMOMOGRAM PREDICTING DISEASE RECURRENCE AFTER HIGH-DOSE BRACHYTHERAPY (2008) (0)
484: Prostate Volume at Initial Biopsy is the Most Important Predictor of Repeat Biopsy Outcome. Validation of a Novel Predictive Tool (2006) (0)
P49 P ROSTATE BIOPSY IIFriday, 20 March, 14.00-15.30, Room A3827 DEVELOPMENT OF AN ACCURATE NOMOGRAM PREDICTING THE PROBABILITY OF PROSTATE CANCER AT SATURATION BIOPSY IN PATIENTS WITH PREVIOUS NEGATIVE BIOPSIES (2009) (0)
19 Age at surgery does not represent an important predictor of stage or biochemical recurrence after radical prostatectomy in European patients and may be safely omitted from prognostic models (2005) (0)
Analysis of T helper type 1 and 2 cells during immunotherapy in patients with Metastatic Renal Cell Carcinoma (MRCC) (2002) (0)
COMPARATIVE ASSESSMENT OF FREE AND TOTAL FORMS OF SERUM HUMAN GLANDULAR KALLIKREIN 2 AND PROSTRATE SPECIFIC ANTIGEN FOR PREDICTION OF LOCALLY ADVANCED AND RECURRENT PROSTATE CANCER (2006) (0)
79 Molecular profiling of laser-microdissected early stage prostate carcinomas (2005) (0)
MORE EXTENSIVE BIOPSY SCHEMES DO NOT INCREASE THE RATE OF AGREEMENT BETWEEN BIOPSY AND FINAL PATHOLOGY (2008) (0)
A pre-specified statistical model based on four kallikrein markers in blood to predict advanced pathology on radical prostatectomy. (2018) (0)
777 High incidence of prostate cancer using a saturation biopsy scheme after several negative biopsies (2004) (0)
1034 The 2002 pathologic T2 sub stages confer no prognostic information on the rate of biochemical recurrence in patients with pathologically organ confined disease at radical prostatectomy (2005) (0)
1303 RADICAL PROSTATECTOMY IN MEN WITH CONTINUES ORAL ASPIRIN MEDICATION: REVISITING OLD PARADIGM? (2011) (0)
Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer (2019) (0)
Prospective evaluation of high-grade prostatic intraepithelial neoplasia in prostate biopsies from cystoprostatectomies (2002) (0)
733 A tertiary Gleason pattern exerts a different prognostic effect after radical prostatectomy in patients with different Gleason scores (2014) (0)
Chromosomal deletions, tumor phenotype, and prognosis in prostate cancer. (2011) (0)
MP11-17 RADICAL PROSTATECTOMY AFTER PREVIOUS TUR-P: ONCOLOGICAL, SURGICAL AND FUNCTIONAL OUTCOMES (2018) (0)
Incidence, risk factors, management and complications of rectal injuries during radical prostatectomy (2017) (0)
862: Comparative Evaluation of Free and Total Forms of Serum Human Glandular Kallikrein 2 and Prostrate Specific Antigen: Which Marker Should we Trust for Prediction of Locally Advanced and Recurrent Prostate Cancer? (2006) (0)
824: Incidence, Preoperative and Postoperative Characteristics of Clinically Insignificant Prostate Cancer in the 2-4NG/ML Range Compared to The 4-10Ng/Ml Range of TPSA (2004) (0)
416 Does increasing life expectancy effect competing mortality after radical prostatectomy (2014) (0)
133 Ability of complexed PSA to differentiate between prostate cancer and benign hyperplasia (2004) (0)
619 THE RISK OF GLEASON SUM UPGRADING REPRESENTS AN IMPORTANT CONSIDERATION IN PATIENTS ELIGIBLE FOR LOW DOSE BRACHYTHERAPY (2010) (0)
Impact of bilateral neurovascular bundle preservation on oncological outcomes in non-organ confined prostate cancer patients (2019) (0)
466Correlation of gene expression and genetic alterations in bladder carcinoma (2005) (0)
The AJCC 8th edition no longer substages pT2 prostate cancer: Does extent of tumor involvement not matter? (2019) (0)
356 RISK-FACTORS FOR BIOCHEMICAL RECURRENCE- AND CLINICAL METASTASIS-FREE SURVIVAL IN D'AMICO HIGH-RISK PATIENTS AFTER RADICAL PROSTATECTOMY (2013) (0)
IMPACT OF ADDITIONAL RADIATION AND/OR ADT ON FUNCTIONAL OUTCOMES AFTER RADICAL PROSTATECTOMY: MP47‐03 (2017) (0)
1031: Comparison of Stage Migration Patterns Between North America and Europe: An Analysis of 11350 Men (2007) (0)
974 Long-term prediction of biochemical recurrence in patients with pathologically organ confined prostate cancer (2012) (0)
756 A RISK ADJUSTED FOLLOW UP SCHEME AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Hartwig Huland?

Hartwig Huland is affiliated with the following schools:

University of Michigan
Free University of Berlin
University of Hamburg
University of Ferrara
Université Laval

Hartwig Huland's Academic­Influence.com Rankings

Hartwig Huland's Degrees

Why Is Hartwig Huland Influential?

Hartwig Huland's Published Works

Published Works

What Schools Are Affiliated With Hartwig Huland?

Hartwig Huland's AcademicInfluence.com Rankings